<html lang="en" class="pb-page js" data-request-id="94d673c4956d77c0-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d673c4956d77c0-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/ExeHIabJo7jGLPM_LPxejZd1NmLiCqkstgbi8ayKYeZnZc7IMZmxICm55jV05PzxQx1tSLXpSWwgQw7vEZAN-w=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d673c4956d77c0-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.2570735650433914"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="topics" content="Vaccines|Global Health|HIV/AIDS">
<meta name="articleCategory" content="Research">
<meta name="articleType" content="Original Article">
<meta name="Specialties" content="Infectious Disease"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2031499","title":"Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults","category":"Research","type":"Original Article","topics":"Vaccines|Global Health|HIV/AIDS","specialties":"Infectious Disease","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2021-03-25T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"topics\" content\u003d\"Vaccines|Global Health|HIV/AIDS\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"Specialties\" content\u003d\"Infectious Disease\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2031499","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[{"type":"Quick Take","title":"Vaccine Efficacy of ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120–MF59 in HIV-Uninfected Adults — HVTN 702","doi":"10.1056/NEJMdo005972","issueDate":"2021-03-25T00:00Z","age":"6Months-1990","isFree":"n","topics":"Vaccines|Global Health|HIV/AIDS","viewType":"Full","specialties":"Infectious Disease"},{"type":"Research Summary","title":"Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults","doi":"10.1056/NEJMdo006028","issueDate":"2021-03-25T00:00Z","age":"6Months-1990","isFree":"n","topics":"Vaccines|Global Health|HIV/AIDS","viewType":"Full","specialties":"Infectious Disease"}]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d673c4956d77c0-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults"><meta name="dc.Creator" content="Glenda E. Gray"><meta name="dc.Creator" content="Linda-Gail Bekker"><meta name="dc.Creator" content="Fatima Laher"><meta name="dc.Creator" content="Mookho Malahleha"><meta name="dc.Creator" content="Mary Allen"><meta name="dc.Creator" content="Zoe Moodie"><meta name="dc.Creator" content="Nicole Grunenberg"><meta name="dc.Creator" content="Yunda Huang"><meta name="dc.Creator" content="Doug Grove"><meta name="dc.Creator" content="Brittany Prigmore"><meta name="dc.Creator" content="Jia J. Kee"><meta name="dc.Creator" content="David Benkeser"><meta name="dc.Creator" content="John Hural"><meta name="dc.Creator" content="Craig Innes"><meta name="dc.Creator" content="Erica Lazarus"><meta name="dc.Creator" content="Graeme Meintjes"><meta name="dc.Creator" content="Nivashnee Naicker"><meta name="dc.Creator" content="Dishiki Kalonji"><meta name="dc.Creator" content="Maphoshane Nchabeleng"><meta name="dc.Creator" content="Modulakgotla Sebe"><meta name="dc.Creator" content="Nishanta Singh"><meta name="dc.Creator" content="Philip Kotze"><meta name="dc.Creator" content="Sheetal Kassim"><meta name="dc.Creator" content="Thozama Dubula"><meta name="dc.Creator" content="Vimla Naicker"><meta name="dc.Creator" content="William Brumskine"><meta name="dc.Creator" content="Cleon N. Ncayiya"><meta name="dc.Creator" content="Amy M. Ward"><meta name="dc.Creator" content="Nigel Garrett"><meta name="dc.Creator" content="Girisha Kistnasami"><meta name="dc.Creator" content="Zakir Gaffoor"><meta name="dc.Creator" content="Pearl Selepe"><meta name="dc.Creator" content="Philisiwe B. Makhoba"><meta name="dc.Creator" content="Matsontso P. Mathebula"><meta name="dc.Creator" content="Pamela Mda"><meta name="dc.Creator" content="Tania Adonis"><meta name="dc.Creator" content="Katlego S. Mapetla"><meta name="dc.Creator" content="Bontle Modibedi"><meta name="dc.Creator" content="Tricia Philip"><meta name="dc.Creator" content="Gladys Kobane"><meta name="dc.Creator" content="Carter Bentley"><meta name="dc.Creator" content="Shelly Ramirez"><meta name="dc.Creator" content="Simbarashe Takuva"><meta name="dc.Creator" content="Megan Jones"><meta name="dc.Creator" content="Mpho Sikhosana"><meta name="dc.Creator" content="Millicent Atujuna"><meta name="dc.Creator" content="Michele Andrasik"><meta name="dc.Creator" content="Nima S. Hejazi"><meta name="dc.Creator" content="Adrian Puren"><meta name="dc.Creator" content="Lubbe Wiesner"><meta name="dc.Creator" content="Sanjay Phogat"><meta name="dc.Creator" content="Carlos Diaz Granados"><meta name="dc.Creator" content="Marguerite Koutsoukos"><meta name="dc.Creator" content="Olivier Van Der Meeren"><meta name="dc.Creator" content="Susan W. Barnett"><meta name="dc.Creator" content="Niranjan Kanesa-Thasan"><meta name="dc.Creator" content="James G. Kublin"><meta name="dc.Creator" content="M. Juliana McElrath"><meta name="dc.Creator" content="Peter B. Gilbert"><meta name="dc.Creator" content="Holly Janes"><meta name="dc.Creator" content="Lawrence Corey"><meta name="dc.Description" content="A safe, effective vaccine is essential to eradicating human immunodeficiency virus (HIV) infection. A canarypox–protein HIV vaccine regimen (ALVAC-HIV plus AIDSVAX B/E) showed modest efficacy in re..."><meta name="Description" content="A safe, effective vaccine is essential to eradicating human immunodeficiency virus (HIV) infection. A canarypox–protein HIV vaccine regimen (ALVAC-HIV plus AIDSVAX B/E) showed modest efficacy in re..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2021-03-25"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2031499"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202103253841206"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="10.1056/NEJMe2102358"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2021 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2031499">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2031499">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2031499">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults | NEJM">
        <meta property="og:title" content="Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2031499">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/2cd64952-8529-4ebb-b4c1-7cb0e8086e5f/nejmoa2031499_f0.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/2cd64952-8529-4ebb-b4c1-7cb0e8086e5f/nejmoa2031499_f0.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="A safe, effective vaccine is essential to eradicating human immunodeficiency virus
(HIV) infection. A canarypox–protein HIV vaccine regimen (ALVAC-HIV plus AIDSVAX B/E)
showed modest efficacy in re...">
        <meta name="twitter:description" content="A safe, effective vaccine is essential to eradicating human immunodeficiency virus
(HIV) infection. A canarypox–protein HIV vaccine regimen (ALVAC-HIV plus AIDSVAX B/E)
showed modest efficacy in re...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="3416">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="citation_fulltext_world_readable" content="">
    <meta name="publication_doi" content="10.1056/NEJMoa2031499">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2031499">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:doi\:10.1056/nejm_2021.384.issue-12;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;article:article:doi\:10.1056/NEJMoa2031499;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2031499" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2031499" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2031499" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2031499" class="inputDoi"><input type="hidden" value="G.E. Gray and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2021;384:1089-1100" class="inputCitation"><input type="hidden" value="03-24-2021" class="inputEPubDate"><input type="hidden" value="March 2021" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d673c4956d77c0-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Glenda E.</span> <span property="familyName">Gray</span>, <span property="honorificSuffix">M.B., B.Ch.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-4649-1477" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-4649-1477</a></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Linda-Gail</span> <span property="familyName">Bekker</span>, <span property="honorificSuffix">M.B., Ch.B., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Fatima</span> <span property="familyName">Laher</span>, <span property="honorificSuffix">M.B., B.Ch.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Mookho</span> <span property="familyName">Malahleha</span>, <span property="honorificSuffix">M.B., Ch.B., M.P.H.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Mary</span> <span property="familyName">Allen</span>, <span property="honorificSuffix">B.S.N., M.S.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Zoe</span> <span property="familyName">Moodie</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Nicole</span> <span property="familyName">Grunenberg</span>, <span property="honorificSuffix">M.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+54</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Yunda</span> <span property="familyName">Huang</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Doug</span> <span property="familyName">Grove</span>, <span property="honorificSuffix">M.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Brittany</span> <span property="familyName">Prigmore</span>, <span property="honorificSuffix">M.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jia J.</span> <span property="familyName">Kee</span>, <span property="honorificSuffix">M.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">David</span> <span property="familyName">Benkeser</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">John</span> <span property="familyName">Hural</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Craig</span> <span property="familyName">Innes</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Erica</span> <span property="familyName">Lazarus</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Graeme</span> <span property="familyName">Meintjes</span>, <span property="honorificSuffix">M.B., Ch.B., M.P.H., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Nivashnee</span> <span property="familyName">Naicker</span>, <span property="honorificSuffix">M.B., Ch.B., M.P.H.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Dishiki</span> <span property="familyName">Kalonji</span>, <span property="honorificSuffix">M.B., B.Ch.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Maphoshane</span> <span property="familyName">Nchabeleng</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Modulakgotla</span> <span property="familyName">Sebe</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Nishanta</span> <span property="familyName">Singh</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Philip</span> <span property="familyName">Kotze</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sheetal</span> <span property="familyName">Kassim</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Thozama</span> <span property="familyName">Dubula</span>, <span property="honorificSuffix">M.Med.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Vimla</span> <span property="familyName">Naicker</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">William</span> <span property="familyName">Brumskine</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Cleon N.</span> <span property="familyName">Ncayiya</span>, <span property="honorificSuffix">B.Sc.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Amy M.</span> <span property="familyName">Ward</span>, <span property="honorificSuffix">M.B., B.Ch.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Nigel</span> <span property="familyName">Garrett</span>, <span property="honorificSuffix">M.B., B.S., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Girisha</span> <span property="familyName">Kistnasami</span>, <span property="honorificSuffix">B.Sc.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Zakir</span> <span property="familyName">Gaffoor</span>, <span property="honorificSuffix">M.Sc.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Pearl</span> <span property="familyName">Selepe</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Philisiwe B.</span> <span property="familyName">Makhoba</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Matsontso P.</span> <span property="familyName">Mathebula</span>, <span property="honorificSuffix">M.B., Ch.B., M.P.H.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Pamela</span> <span property="familyName">Mda</span>, <span property="honorificSuffix">M.B., Ch.B., M.Med.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Tania</span> <span property="familyName">Adonis</span>, <span property="honorificSuffix">B.Psych.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Katlego S.</span> <span property="familyName">Mapetla</span>, <span property="honorificSuffix">B.Tech.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Bontle</span> <span property="familyName">Modibedi</span>, <span property="honorificSuffix">R.N.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Tricia</span> <span property="familyName">Philip</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Gladys</span> <span property="familyName">Kobane</span>, <span property="honorificSuffix">R.N.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Carter</span> <span property="familyName">Bentley</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Shelly</span> <span property="familyName">Ramirez</span>, <span property="honorificSuffix">M.A.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Simbarashe</span> <span property="familyName">Takuva</span>, <span property="honorificSuffix">M.B., Ch.B.</span> <a class="orcid-id" href="https://orcid.org/0000-0001-6030-2359" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0001-6030-2359</a></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Megan</span> <span property="familyName">Jones</span>, <span property="honorificSuffix">B.S.N., M.P.H.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Mpho</span> <span property="familyName">Sikhosana</span>, <span property="honorificSuffix">M.B., B.Ch., M.P.H.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Millicent</span> <span property="familyName">Atujuna</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Michele</span> <span property="familyName">Andrasik</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Nima S.</span> <span property="familyName">Hejazi</span>, <span property="honorificSuffix">M.A.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-7127-2789" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-7127-2789</a></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Adrian</span> <span property="familyName">Puren</span>, <span property="honorificSuffix">M.B., B.Ch., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Lubbe</span> <span property="familyName">Wiesner</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sanjay</span> <span property="familyName">Phogat</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Carlos</span> <span property="familyName">Diaz Granados</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Marguerite</span> <span property="familyName">Koutsoukos</span>, <span property="honorificSuffix">M.Sc.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Olivier</span> <span property="familyName">Van Der Meeren</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-0291-743X" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-0291-743X</a></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Susan W.</span> <span property="familyName">Barnett</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Niranjan</span> <span property="familyName">Kanesa-Thasan</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">James G.</span> <span property="familyName">Kublin</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">M. Juliana</span> <span property="familyName">McElrath</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Peter B.</span> <span property="familyName">Gilbert</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Holly</span> <span property="familyName">Janes</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Lawrence</span> <span property="familyName">Corey</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-2179-2436" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-2179-2436</a></span></span>, for <span property="author" typeof="Person" role="listitem">the HVTN 702 Study Team<sup><a href="#fn1" role="doc-noteref">*</a></sup></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-54</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">March 24, 2021</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2021<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">384</span></span>:<span property="pageStart">1089</span>-<span property="pageEnd">1100</span></div><div class="doi">DOI: 10.1056/NEJMoa2031499</div><div class="core-enumeration"><a href="/toc/nejm/384/12"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">384</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">12</span></span></a></div><div><a href="#tab-information">Copyright © 2021</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DGlenda%2BE.%2BGray%252C%2BLinda-Gail%2BBekker%252C%2BFatima%2BLaher%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D384%26issueNum%3D12%26contentID%3D10.1056%252FNEJMoa2031499%26title%3DVaccine%2BEfficacy%2Bof%2BALVAC-HIV%2Band%2BBivalent%2BSubtype%2BC%2Bgp120%25E2%2580%2593MF59%2Bin%2BAdults%26publicationDate%3D03%252F25%252F2021" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2031499" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DGlenda%2BE.%2BGray%252C%2BLinda-Gail%2BBekker%252C%2BFatima%2BLaher%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D384%26issueNum%3D12%26contentID%3D10.1056%252FNEJMoa2031499%26title%3DVaccine%2BEfficacy%2Bof%2BALVAC-HIV%2Band%2BBivalent%2BSubtype%2BC%2Bgp120%25E2%2580%2593MF59%2Bin%2BAdults%26publicationDate%3D03%252F25%252F2021" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/87c696af-25fe-4d22-b913-6d8bea675e92/nejmoa2031499.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2031499.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2031499" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2031499" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2031499.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">A safe, effective vaccine is essential to eradicating human immunodeficiency virus (HIV) infection. A canarypox–protein HIV vaccine regimen (ALVAC-HIV plus AIDSVAX B/E) showed modest efficacy in reducing infection in Thailand. An analogous regimen using HIV-1 subtype C virus showed potent humoral and cellular responses in a phase 1–2a trial in South Africa. Efficacy data and additional safety data were needed for this regimen in a larger population in South Africa.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">In this phase 2b–3 trial, we randomly assigned 5404 adults without HIV-1 infection to receive the vaccine (2704 participants) or placebo (2700 participants). The vaccine regimen consisted of injections of ALVAC-HIV at months 0 and 1, followed by four booster injections of ALVAC-HIV plus bivalent subtype C gp120–MF59 adjuvant at months 3, 6, 12, and 18. The primary efficacy outcome was the occurrence of HIV-1 infection from randomization to 24 months.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><!-- There is no content. --><nav><a href="#f0" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2031499_f0.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f0" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2031499_f0.jpg"><img src="/cms/10.1056/NEJMoa2031499/asset/2cd64952-8529-4ebb-b4c1-7cb0e8086e5f/assets/images/large/nejmoa2031499_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"></a><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></figure></div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">In January 2020, prespecified criteria for nonefficacy were met at an interim analysis; further vaccinations were subsequently halted. The median age of the trial participants was 24 years; 70% of the participants were women. The incidence of adverse events was similar in the vaccine and placebo groups. During the 24-month follow-up, HIV-1 infection was diagnosed in 138 participants in the vaccine group and in 133 in the placebo group (hazard ratio, 1.02; 95% confidence interval, 0.81 to 1.30; P=0.84).</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">The ALVAC–gp120 regimen did not prevent HIV-1 infection among participants in South Africa despite previous evidence of immunogenicity. (HVTN 702 ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT02968849" target="_blank">NCT02968849</a>.)</div></section></section><div class="core-digital-object quick-take">
<div class="ng-do-media" style="border-top: 1px solid #e5e5e5; padding-top: 1.5rem;" data-location="inlineArticlePreview">
    <div class="ng-do-media_item">
        <div class="ng-do-media_item-left">
            <a href="/do/10.1056/NEJMdo005972/full/" class="ng-do-media_item-img-link">
                <img src="/cms/asset/d3afbb04-4fea-4eb3-a4ff-b7ac9840b8b4/media/NEJMdo005972_300x200.jpg" class="ng-do-media_item-img">
                <span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#tooltip-video"></use></svg></span>
            </a>
        </div>
        <div class="ng-do-media_item-right">
            <div class="ng-do-media_item-type">
                <a href="/browse/nejm-media-type/quick-take" class="ng-do-media_item-type-link">Quick Take</a>
            </div>
            <h6 class="ng-do-media_item-title">
                <a href="/do/10.1056/NEJMdo005972/full/" class="ng-do-media_item-title-link">Vaccine Efficacy of ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120–MF59 in HIV-Uninfected Adults — HVTN 702</a>
            </h6>
            <div class="ng-do-media_item-duration">2m 7s</div>
        </div>
    </div>
</div>
</div></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Most of the 75.7 million persons with human immunodeficiency virus (HIV) infection worldwide are in sub-Saharan Africa, where subtype C of HIV type 1 (HIV-1) is prevalent.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1" href-manipulated="true" aria-label="Reference 1">1</a></sup> A disproportionately large number of persons with HIV-1 (approximately 7.9 million) live in South Africa, which highlights the urgent need for a vaccine in this country and elsewhere.<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2" id="body-ref-r2" href-manipulated="true" aria-label="Reference 2">2</a></sup></div><div role="paragraph">In 2010, after the announcement that the community-based RV144 HIV vaccine trial had shown 31% efficacy in Thailand,<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3" id="body-ref-r3" href-manipulated="true" aria-label="Reference 3">3</a></sup> the Pox Protein Public–Private Partnership (P5) was established. The P5 developed an analogous regimen with the use of HIV-1 subtype C sub-Saharan African strains, including a transmitted-founder isolate.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4" id="body-ref-r4" href-manipulated="true" aria-label="Reference 4">4</a></sup> The vaccines, which were administered sequentially, were a recombinant canarypox vector containing subtype C envelope ALVAC-HIV (vCP2438) and an MF59-adjuvanted subtype C bivalent glycoprotein 120 (gp120) vaccine. In a phase 1–2a trial, this vaccine regimen was found to be safe and induced strong humoral and cellular immune responses.<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5" id="body-ref-r5" href-manipulated="true" aria-label="Reference 5">5</a></sup> In the phase 2b–3 HIV Vaccine Trials Network (HVTN) 702 trial, we investigated the safety and efficacy of this vaccine regimen with respect to HIV-1 acquisition in South Africa.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Trial Design and Randomization</h3><div role="paragraph">From October 26, 2016, to June 21, 2019, we conducted this randomized, double-blind, placebo-controlled trial at 14 sites in South Africa. The research ethics committees of the University of the Witwatersrand, University of Cape Town, University of KwaZulu-Natal, Sefako Makgatho University, and the South African Medical Research Council approved the trial.</div><div role="paragraph">Participants were randomly assigned in a 1:1 ratio to receive the vaccine regimen or placebo, stratified according to sex and site, with centrally generated randomization by the Statistical Center for HIV–AIDS Research and Prevention (SCHARP). The trial was designed to evaluate vaccine efficacy to prevent HIV-1 infection within 24 months after enrollment, with formal monitoring for potential harm, nonefficacy, and high efficacy, with potential to extend follow-up to 36 months for all participants.<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6" id="body-ref-r6" href-manipulated="true" aria-label="Reference 6">6</a></sup></div></section><section id="sec-1-2"><h3>Trial Population</h3><div role="paragraph">Eligible participants were healthy adults between the ages of 18 and 35 years without HIV-1 infection. We aimed to have a trial population in which 60 to 75% of the participants were women. (In this report, women and men are identified according to the sex they were assigned at birth.) Women who had reproductive potential were required to use contraception until 3 months after the final vaccination; pregnant or breast-feeding women were excluded from the trial. All the participants provided written informed consent in their preferred language.</div></section><section id="sec-1-3"><h3>Intervention</h3><div role="paragraph">The vaccine regimen consisted of an ALVAC-HIV vector and an MF59-adjuvanted bivalent subtype C gp120. ALVAC-HIV (vCP2438) (at a dose of 10<sup>7</sup> 50% cell-culture infectious dose) expresses the HIV-1 envelope glycoprotein of the subtype C ZM96.C strain, along with the gp41 transmembrane sequence, <i>gag</i>, and <i>protease</i> from the subtype B LAI strain. Bivalent subtype C gp120 is a combination of 100 μg each of the HIV-1 subtype C gp120 of the TV1.C and 1086.C strains. Placebo consisted of 0.9% sodium chloride.</div><div role="paragraph">Participants received an intramuscular injection of ALVAC-HIV or placebo at months 0 and 1, which was followed by four injections of ALVAC-HIV plus bivalent subtype C gp120–MF59 or placebo at months 3, 6, 12, and 18. ALVAC-HIV or placebo was administered in the left deltoid, and bivalent subtype C gp120–MF59 or placebo was administered in the right deltoid.</div></section><section id="sec-1-4"><h3>Primary and Secondary Outcomes</h3><div role="paragraph">The primary efficacy outcome was the occurrence of HIV-1 infection from randomization to 24 months. The primary analysis was conducted in the modified intention-to-treat population, which included all the participants who had undergone randomization with the exception of those in whom HIV-1 infection had been diagnosed at the time of enrollment.</div><div role="paragraph">Secondary analyses were performed in different cohorts and over different time periods. The first secondary analysis was performed in a cohort of participants who were HIV-1–negative at month 6.5 (i.e., 2 weeks after the fourth vaccination) and were at risk for subsequent HIV-1 infection (month 6.5 at-risk cohort). These participants were evaluated between month 6.5 and month 24. The second secondary analysis of vaccine efficacy was performed between randomization and month 36 in the modified intention-to-treat population. The third secondary efficacy analysis was performed between month 6.5 and month 24 in the per-protocol cohort, which included participants in the month 6.5 at-risk cohort who had received the first four vaccinations on schedule and without error. Follow-up time was the number of days from randomization or the month 6.5 visit until the diagnosis of HIV-1 infection or, in participants without such a diagnosis, from randomization or the month 6.5 visit to the last negative test at the end of the evaluation period for that outcome, whichever occurred first. Safety analyses included all the participants who had undergone randomization and received at least one injection of vaccine or placebo and were performed according to the injection received.</div></section><section id="sec-1-5"><h3>Outcome Evaluation</h3><div role="paragraph">Trial visits were scheduled at months 0, 1, 3, 6, 6.5, 12, 12.5, 15, 18, 18.5, and 21 and every 3 months thereafter up to month 36 and included evaluations of vaccine safety. (Details regarding these evaluations are provided in the <a href="#ap1">protocol</a> and the <a href="#ap2">Supplementary Appendix</a>, available with the full text of this article at NEJM.org.) At each visit, we performed a physical examination, counseling regarding HIV risk reduction, pregnancy assessment, assessment of the social effect of participation in the vaccine trial, monitoring of adverse events, and information regarding concomitant medications. HIV testing with counseling occurred every 3 months, testing for sexually transmitted infection was performed every 6 months, and a behavioral-risk questionnaire was administered at screening and at months 6.5, 12, 24, and 36. Access to free preexposure prophylaxis and postexposure prophylaxis (PrEP–PEP) was provided. Trial vaccinations were prohibited in women who became pregnant or initiated breast-feeding during the trial.</div></section><section id="sec-1-6"><h3>Laboratory Methods</h3><div role="paragraph">Testing for HIV types 1 and 2 was performed at trial sites to avoid potential unblinding of trial-group assignments. HIV infection was confirmed by detection of HIV nucleic acid, and HIV-1 RNA viral loads were measured after diagnosis. An independent adjudication committee reviewed the results of HIV diagnostic testing from specimens collected on at least two dates and made the primary determination regarding infection status and timing. For monitoring the use of PrEP–PEP, dried blood-spot samples were obtained from all the participants who were seen at sites on a given day each month to measure levels of tenofovir diphosphate (TFV-DP).</div></section><section id="sec-1-7"><h3>Trial Oversight</h3><div role="paragraph">The trial was overseen by the data and safety monitoring board of the National Institute of Allergy and Infectious Diseases (NIAID). This board provided recommendations to the HVTN 702 oversight group (which consisted of representatives of the NIAID, HVTN, Bill and Melinda Gates Foundation, Sanofi Pasteur, and GSK), who advised the protocol team and made the final decisions regarding conduct of the trial. All data were collected and analyzed by SCHARP. All the authors had access to the data, conducted a critical review of the manuscript, and approved the decision to submit the manuscript for publication. The first draft of the manuscript was written by the first three authors, the statisticians, and the last author.</div></section><section id="sec-1-8"><h3>Statistical Analysis</h3><div role="paragraph">We determined that a sample size of 5400 participants would provide a power of at least 90% to reject a null hypothesis of vaccine efficacy between randomization and 24 months (the primary measure of vaccine efficacy) of 25% or less if the true vaccine efficacy was 50% or more, assuming an annual HIV-1 incidence of 4% in the placebo group (Tables S2 and S3 in the <a href="#ap2">Supplementary Appendix</a>). Vaccine efficacy was calculated as 1 minus the hazard ratio for HIV-1 infection, which we estimated using a sex-stratified Cox proportional-hazards model and tested using a sex-stratified log-rank test. We also measured vaccine efficacy using a ratio of cumulative incidences of HIV-1 infection in the vaccine group as compared with the placebo group; we calculated this measure using Nelson–Aalen cumulative hazard estimates. We used the Kaplan–Meier method to estimate the cumulative incidence of HIV-1 infection and loss to follow-up. We performed Wald interaction tests to evaluate prespecified baseline variables as modifiers of vaccine efficacy, using stratified Cox proportional-hazards models and the Holm method<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7" id="body-ref-r7" href-manipulated="true" aria-label="Reference 7">7</a></sup> to adjust for multiple comparisons.</div><div role="paragraph">We monitored for a potential increase in the risk of HIV-1 infection induced by the vaccine, beginning after the diagnosis of 12 infections and continuing until the initiation of nonefficacy monitoring, which began after the diagnosis of 59 infections. The prespecified stopping criteria for nonefficacy were a lower limit of the 95% confidence intervals of less than 0% and an upper limit of less than 40% in both the modified intention-to-treat population and the month 6.5 at-risk cohort on the basis of both the Cox proportional-hazards analysis and the cumulative-incidence-ratio estimation. Nonefficacy criteria also required that at least 60% of the enrolled participants had reached the month 18.5 visit.</div><div role="paragraph">All P values are two-sided, and a P value of less than 0.05 was considered to indicate statistical significance. Additional details regarding the statistical analysis are provided in the <a href="#ap2">Supplementary Appendix</a>.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Trial Participants</h3><div role="paragraph">During the trial period, 9918 persons were screened and 5407 were enrolled (Fig. S1). Of these participants, 3 were enrolled twice, and only data from the first enrollment were used. Of the 5404 unique participants enrolled, 2704 were assigned to the vaccine group and 2700 to the placebo group. The cutoff date for the data that are presented here was February 18, 2020, before the unblinding of the trial on February 19, 2020.</div><div role="paragraph">Data regarding demographic and clinical characteristics and HIV-1 risk factors were similar in the two trial groups (<a href="#t1">Table 1</a>). Overall, 3786 participants (70%) were female, and of these women, 1115 (29%) were between the ages of 18 and 21 years. Male participants tended to be older, with 859 of 1618 (53%) at least 26 years of age. At enrollment, sexually transmitted diseases were diagnosed in 1003 of 3389 women (30%) and in 228 of 1254 men (18%). Detailed characteristics of the participants at baseline are provided in Tables S4 through S9.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2031499_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2031499_t1.jpg"><img src="/cms/10.1056/NEJMoa2031499/asset/0e2f6395-5b0b-4cd6-b251-c8c0023eb55f/assets/images/large/nejmoa2031499_t1.jpg" height="2361" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders" colspan="3"><span>Women</span></th><th class="txxr-borders" colspan="3"><span>Men</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Total<br>(N=3786)</th><th class="xxxx-borders">Vaccine<br>(N=1893)</th><th class="xxxx-borders">Placebo<br>(N=1893)</th><th class="xxxx-borders">Total<br>(N=1618)</th><th class="xxxx-borders">Vaccine<br>(N=811)</th><th class="xxxr-borders">Placebo<br>(N=807)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading">Age group — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">18–21 yr</td><td class="xxxx-borders">1115 (29)</td><td class="xxxx-borders">543 (29)</td><td class="xxxx-borders">572 (30)</td><td class="xxxx-borders">321 (20)</td><td class="xxxx-borders">166 (20)</td><td class="xxxr-borders">155 (19)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">22–25 yr</td><td class="xxxx-borders shading">1420 (38)</td><td class="xxxx-borders shading">723 (38)</td><td class="xxxx-borders shading">697 (37)</td><td class="xxxx-borders shading">438 (27)</td><td class="xxxx-borders shading">219 (27)</td><td class="xxxr-borders shading">219 (27)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">26–35 yr</td><td class="xxxx-borders">1251 (33)</td><td class="xxxx-borders">627 (33)</td><td class="xxxx-borders">624 (33)</td><td class="xxxx-borders">859 (53)</td><td class="xxxx-borders">426 (53)</td><td class="xxxr-borders">433 (54)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Body-mass index — no. (%)<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">&lt;18.5</td><td class="xxxx-borders">133 (4)</td><td class="xxxx-borders">56 (3)</td><td class="xxxx-borders">77 (4)</td><td class="xxxx-borders">232 (14)</td><td class="xxxx-borders">114 (14)</td><td class="xxxr-borders">118 (15)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">18.5–24</td><td class="xxxx-borders shading">1406 (37)</td><td class="xxxx-borders shading">725 (38)</td><td class="xxxx-borders shading">681 (36)</td><td class="xxxx-borders shading">1127 (70)</td><td class="xxxx-borders shading">560 (69)</td><td class="xxxr-borders shading">567 (70)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">25–29</td><td class="xxxx-borders">978 (26)</td><td class="xxxx-borders">493 (26)</td><td class="xxxx-borders">485 (26)</td><td class="xxxx-borders">194 (12)</td><td class="xxxx-borders">97 (12)</td><td class="xxxr-borders">97 (12)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">≥30</td><td class="xxxx-borders shading">1269 (34)</td><td class="xxxx-borders shading">619 (33)</td><td class="xxxx-borders shading">650 (34)</td><td class="xxxx-borders shading">65 (4)</td><td class="xxxx-borders shading">40 (5)</td><td class="xxxr-borders shading">25 (3)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Gender identity — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Female</td><td class="xxxx-borders shading">3783 (100)</td><td class="xxxx-borders shading">1892 (100)</td><td class="xxxx-borders shading">1891 (100)</td><td class="xxxx-borders shading">6 (&lt;1)</td><td class="xxxx-borders shading">5 (1)</td><td class="xxxr-borders shading">1 (&lt;1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Male</td><td class="xxxx-borders">2 (&lt;1)</td><td class="xxxx-borders">1 (&lt;1)</td><td class="xxxx-borders">1 (&lt;1)</td><td class="xxxx-borders">1598 (99)</td><td class="xxxx-borders">801 (99)</td><td class="xxxr-borders">797 (99)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Transgender female or male</td><td class="xxxx-borders shading">1 (&lt;1)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (&lt;1)</td><td class="xxxx-borders shading">10 (1)</td><td class="xxxx-borders shading">4 (&lt;1)</td><td class="xxxr-borders shading">6 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Gender variant</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">2 (&lt;1)</td><td class="xxxx-borders">1 (&lt;1)</td><td class="xxxr-borders">1 (&lt;1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Prefer not to answer</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (&lt;1)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">2 (&lt;1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Condom use — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Always</td><td class="xxxx-borders shading">209 (6)</td><td class="xxxx-borders shading">88 (5)</td><td class="xxxx-borders shading">121 (6)</td><td class="xxxx-borders shading">140 (9)</td><td class="xxxx-borders shading">79 (10)</td><td class="xxxr-borders shading">61 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Sometimes</td><td class="xxxx-borders">2790 (74)</td><td class="xxxx-borders">1411 (75)</td><td class="xxxx-borders">1379 (73)</td><td class="xxxx-borders">1228 (76)</td><td class="xxxx-borders">601 (74)</td><td class="xxxr-borders">627 (78)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Never</td><td class="xxxx-borders shading">786 (21)</td><td class="xxxx-borders shading">393 (21)</td><td class="xxxx-borders shading">393 (21)</td><td class="xxxx-borders shading">249 (15)</td><td class="xxxx-borders shading">130 (16)</td><td class="xxxr-borders shading">119 (15)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Exchange of sex for money or gifts in past 30 days — no. (%)</td><td class="xxxx-borders">791 (21)</td><td class="xxxx-borders">384 (20)</td><td class="xxxx-borders">407 (22)</td><td class="xxxx-borders">256 (16)</td><td class="xxxx-borders">128 (16)</td><td class="xxxr-borders">128 (16)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Number of sex acts in past 30 days — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">0–4</td><td class="xxxx-borders">1238 (33)</td><td class="xxxx-borders">624 (33)</td><td class="xxxx-borders">614 (32)</td><td class="xxxx-borders">455 (28)</td><td class="xxxx-borders">229 (28)</td><td class="xxxr-borders">226 (28)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">5–10</td><td class="xxxx-borders shading">1373 (36)</td><td class="xxxx-borders shading">702 (37)</td><td class="xxxx-borders shading">671 (35)</td><td class="xxxx-borders shading">609 (38)</td><td class="xxxx-borders shading">310 (38)</td><td class="xxxr-borders shading">299 (37)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">≥11</td><td class="xxxx-borders">1173 (31)</td><td class="xxxx-borders">567 (30)</td><td class="xxxx-borders">606 (32)</td><td class="xxxx-borders">554 (34)</td><td class="xxxx-borders">272 (34)</td><td class="xxxr-borders">282 (35)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Lives with spouse or main partner — no. (%)</td><td class="xxxx-borders shading">530 (14)</td><td class="xxxx-borders shading">239 (13)</td><td class="xxxx-borders shading">291 (15)</td><td class="xxxx-borders shading">278 (17)</td><td class="xxxx-borders shading">144 (18)</td><td class="xxxr-borders shading">134 (17)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Sexually transmitted infection — no./total no. (%)<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Syphilis</td><td class="xxxx-borders shading">44/3389 (1)</td><td class="xxxx-borders shading">21/1702 (1)</td><td class="xxxx-borders shading">23/1687 (1)</td><td class="xxxx-borders shading">26/1252 (2)</td><td class="xxxx-borders shading">10/633 (2)</td><td class="xxxr-borders shading">16/619 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>Neisseria gonorrhoeae</i></td><td class="xxxx-borders">179/3389 (5)</td><td class="xxxx-borders">90/1702 (5)</td><td class="xxxx-borders">89/1687 (5)</td><td class="xxxx-borders">39/1252 (3)</td><td class="xxxx-borders">19/633 (3)</td><td class="xxxr-borders">20/619 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>Chlamydia trachomatis</i></td><td class="xxxx-borders shading">779/3389 (23)</td><td class="xxxx-borders shading">408/1702 (24)</td><td class="xxxx-borders shading">371/1687 (22)</td><td class="xxxx-borders shading">199/1252 (16)</td><td class="xxxx-borders shading">103/633 (16)</td><td class="xxxr-borders shading">96/619 (16)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left"><i>Trichomonas vaginalis</i></td><td class="xbxx-borders">192/3389 (6)</td><td class="xbxx-borders">97/1702 (6)</td><td class="xbxx-borders">95/1687 (6)</td><td class="xbxx-borders">NA</td><td class="xbxx-borders">NA</td><td class="xbxr-borders">NA</td></tr></tbody></table></div><figcaption><div class="caption">Characteristics of the Participants at Baseline, According to Sex.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Percentages may not total 100 because of rounding. NA denotes not applicable.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">The body-mass index is the weight in kilograms divided by the square of the height in meters.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">Testing for sexually transmitted infections was introduced in version 2 of the protocol, so data are not available for 763 trial participants (397 women and 366 men).</div></div></div></figcaption></figure></div><div role="paragraph">The modified intention-to-treat cohort included 5384 participants (2695 in the vaccine group and 2689 in the placebo group) who were followed for a median of 623 days (interquartile range [IQR], 427 to 819). The median follow-up was 642 days (IQR, 459 to 756) in the month 6.5 at-risk cohort and 644 days (IQR, 461 to 756) in the per-protocol cohort. The rate of loss to follow-up was 3.9 per 100 person-years in each of the two groups (Fig. S2). Adherence to the protocol was high among the participants (Tables S10 and S11).</div></section><section id="sec-2-2"><h3>Efficacy against HIV-1 Infection</h3><div role="paragraph">During the first 24 months of follow-up, 138 HIV-1 infections occurred in the vaccine group and 133 in the placebo group, for an estimated incidence rate of 3.4 per 100 person-years (95% confidence interval [CI], 2.8 to 4.0) and 3.3 per 100 person-years (95% CI, 2.8 to 3.9), respectively (hazard ratio, 1.02; 95% CI, 0.81 to 1.30; P=0.84) (<a href="#f1">Figure 1A</a> and <a href="#t2">Table 2</a>). The incidence of HIV-1 infection was similar in the vaccine group and the placebo group in secondary analyses during 36 months of follow-up (hazard ratio, 1.05; 95% CI, 0.83 to 1.31), in the month 6.5 at-risk cohort between 6.5 months and 24 months (hazard ratio, 1.15; 95% CI, 0.84 to 1.58), and in the per-protocol cohort, as well as in other secondary analyses (Figs. S3 through S9).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2031499_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2031499_f1.jpg"><img src="/cms/10.1056/NEJMoa2031499/asset/b81de1e2-3439-4d27-adc5-3d454a01dde3/assets/images/large/nejmoa2031499_f1.jpg" height="2663" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Kaplan–Meier Analysis of HIV-1 Infection in Three Cohorts.</div><div class="notes"><div role="doc-footnote">Shown are data for the cumulative incidence of human immunodeficiency virus type 1 (HIV-1) infection among the participants in the modified intention-to-treat cohort who were evaluated during the period from randomization to 24 months (primary analysis cohort) (Panel A), in the cohort of participants who were HIV-1–negative at month 6.5 and were at risk for subsequent HIV-1 infection (month 6.5 at-risk cohort) (Panel B), and in the modified intention-to-treat cohort during the period from randomization to month 36 (Panel C). The apparent uptick in the vaccine curve at month 36 is due to a single infection among the remaining 11 participants at risk. In each panel, the inset shows the same data on an expanded y axis; in Panel C, the vaccine curve at 36 months has been cut off at 10% for graphical presentation.</div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2031499_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2031499_t2.jpg"><img src="/cms/10.1056/NEJMoa2031499/asset/4b8c5f44-9980-40a3-945c-55be1291c3d6/assets/images/large/nejmoa2031499_t2.jpg" height="1451" width="2615" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Cohort and Time Period</th><th class="txxx-borders" colspan="4"><span>Vaccine (N=2695)</span></th><th class="txxx-borders" colspan="4"><span>Placebo (N=2689)</span></th><th class="txxr-borders">Hazard Ratio<br>(95% CI)<a href="#t2fn2" role="doc-noteref">†</a></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Participants<br>Evaluated</th><th class="xxxx-borders">Infections<br>Diagnosed</th><th class="xxxx-borders">Person-Yrs</th><th class="xxxx-borders">Infection Rate</th><th class="xxxx-borders">Participants<br>Evaluated</th><th class="xxxx-borders">Infections<br>Diagnosed</th><th class="xxxx-borders">Person-Yrs</th><th class="xxxx-borders">Infection Rate</th><td class="xxxr-borders">&nbsp;</td></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders" colspan="3"><span>number</span></th><th class="xxxx-borders">number/100<br>person-yr</th><th class="xxxx-borders" colspan="3"><span>number</span></th><th class="xxxx-borders">number/100<br>person-yr</th><td class="xxxr-borders">&nbsp;</td></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">mITT cohort (mo 0–24)</td><td class="xxxx-borders shading">2695</td><td class="xxxx-borders shading">138</td><td class="xxxx-borders shading">4098.3</td><td class="xxxx-borders shading">3.4</td><td class="xxxx-borders shading">2689</td><td class="xxxx-borders shading">133</td><td class="xxxx-borders shading">4052.7</td><td class="xxxx-borders shading">3.3</td><td class="xxxr-borders shading">1.02 (0.81–1.30)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">mITT cohort (mo 0–36)</td><td class="xxxx-borders">2695</td><td class="xxxx-borders">151</td><td class="xxxx-borders">4477.9</td><td class="xxxx-borders">3.4</td><td class="xxxx-borders">2689</td><td class="xxxx-borders">143</td><td class="xxxx-borders">4438.7</td><td class="xxxx-borders">3.2</td><td class="xxxr-borders">1.05 (0.83–1.31)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Month 6.5 at-risk cohort (mo 6.5–24)</td><td class="xxxx-borders shading">2430</td><td class="xxxx-borders shading">83</td><td class="xxxx-borders shading">2804.0</td><td class="xxxx-borders shading">3.0</td><td class="xxxx-borders shading">2393</td><td class="xxxx-borders shading">71</td><td class="xxxx-borders shading">2760.6</td><td class="xxxx-borders shading">2.6</td><td class="xxxr-borders shading">1.15 (0.84–1.58)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Sex of participants in the mITT cohort (mo 0–24)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Female</td><td class="xxxx-borders shading">1887</td><td class="xxxx-borders shading">122</td><td class="xxxx-borders shading">2819.9</td><td class="xxxx-borders shading">4.3</td><td class="xxxx-borders shading">1886</td><td class="xxxx-borders shading">117</td><td class="xxxx-borders shading">2787.3</td><td class="xxxx-borders shading">4.2</td><td class="xxxr-borders shading">1.03 (0.80, 1.33)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Male</td><td class="xxxx-borders">808</td><td class="xxxx-borders">16</td><td class="xxxx-borders">1278.4</td><td class="xxxx-borders">1.3</td><td class="xxxx-borders">803</td><td class="xxxx-borders">16</td><td class="xxxx-borders">1265.5</td><td class="xxxx-borders">1.3</td><td class="xxxr-borders">0.99 (0.50, 1.98)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Age of women in the mITT cohort (mo 0–24)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">≤25 yr</td><td class="xxxx-borders">1264</td><td class="xxxx-borders">87</td><td class="xxxx-borders">1832.1</td><td class="xxxx-borders">4.7</td><td class="xxxx-borders">1267</td><td class="xxxx-borders">80</td><td class="xxxx-borders">1829.6</td><td class="xxxx-borders">4.4</td><td class="xxxr-borders">1.08 (0.80, 1.47)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">&gt;25 yr</td><td class="xbxx-borders shading">623</td><td class="xbxx-borders shading">35</td><td class="xbxx-borders shading">987.8</td><td class="xbxx-borders shading">3.5</td><td class="xbxx-borders shading">619</td><td class="xbxx-borders shading">37</td><td class="xbxx-borders shading">957.7</td><td class="xbxx-borders shading">3.9</td><td class="xbxr-borders shading">0.92 (0.58, 1.46)</td></tr></tbody></table></div><figcaption><div class="caption">Rate of HIV-1 Infection and Estimated Hazard Ratios, According to Cohort and Baseline Variables.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">Data are shown for the modified intention-to-treat (mITT) cohort during the period from randomization to 24 months (primary analysis), in the mITT cohort from randomization to 36 months (secondary analysis), in the month 6.5 at-risk cohort consisting of the mITT participants who were HIV-1–negative at 6.5 months and at risk for subsequent HIV-1 infection (secondary analysis), and in the mITT cohort according to sex and age among the female participants.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">The listed values are hazard ratios for vaccine as compared with placebo, as estimated by the Cox proportional-hazards model. In addition to hazard ratios, cumulative incidence ratio (CIR) estimates were calculated for vaccine efficacy in the mITT cohort during the period from month 0 to 24 (1.03; 95% CI, 0.81 to 1.31), in the mITT cohort from month 0 to 30 (1.05; 95% CI, 0.81 to 1.36), and in the month 6.5 at-risk cohort (1.12; 95% CI, 0.81 to 1.54). The 30-month analysis corresponds to the 36-month analysis by the Cox proportional-hazards model but was estimated over the time period in which there were at least 150 participants at risk in each trial group.</div></div></div></figcaption></figure></div><div role="paragraph">Between randomization and month 24, the vaccine efficacy according to sex was similar in the two groups (P=0.92 for interaction); the estimated hazard ratio was 1.03 (95% CI, 0.80 to 1.33) among women and 0.99 (95% CI, 0.50 to 1.98) among men (<a href="#f2">Figure 2A</a> and <a href="#t2">Table 2</a>). The rate of HIV-1 infection among women was 4.3 per 100 person-years (95% CI, 3.6 to 5.2) in the vaccine group and 4.2 per 100 person-years (95% CI, 3.5 to 5.0) in the placebo group; the respective rates among men were 1.3 per 100 person-years (95% CI, 0.7 to 2.0) and 1.3 per 100 person-years (95% CI, 0.7 to 2.1).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2031499_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2031499_f2.jpg"><img src="/cms/10.1056/NEJMoa2031499/asset/73300005-7fba-465d-90cd-3ea4655629a2/assets/images/large/nejmoa2031499_f2.jpg" height="3076" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Kaplan–Meier Analysis of HIV-1 Infection, According to Sex and Women’s Age.</div><div class="notes"><div role="doc-footnote">Shown is the cumulative incidence of HIV-1 infection in the modified intention-to-treat cohort during the period from randomization to 24 months, according to two prespecified baseline variables: sex (Panel A) and women’s age (Panel B). In each panel, the inset shows the same data on an expanded y axis.</div></div></figcaption></figure></div><div role="paragraph">Secondary analyses also included prespecified assessments of potential modifications in vaccine efficacy among women according to age, baseline HIV-1 risk score, body-mass index, and geographic region from randomization to month 24. None of these factors were found to modify the vaccine efficacy after adjustment for multiple comparisons (P≥0.09) (Table S12).</div></section><section id="sec-2-3"><h3>Postinfection Viral Load</h3><div role="paragraph">Among the 294 participants who were included in the modified intention-to-treat population and who were found to have HIV-1 infection during 36 months of follow-up, the mean log<sub>10</sub> viral load at the time of diagnosis was similar in the vaccine group and in the placebo group, with 4.82 log<sub>10</sub> copies per milliliter (95% CI, 4.61 to 5.02) and 4.64 log<sub>10</sub> copies per milliliter (95% CI, 4.45 to 4.84), respectively (Table S13 and Fig. S10). The median time until the initiation of antiretroviral therapy was 13 weeks in the vaccine group and 14 weeks in the placebo group (Fig. S11).</div></section><section id="sec-2-4"><h3>Use of PrEP–PEP</h3><div role="paragraph">Despite the availability of PrEP–PEP at no cost to all the participants, the overall use of PrEP as reported by the participants was low (in 120 women [3%] and 52 men [3%]), as was the use of PEP (in 91 women [2%] and 80 men [5%]) (Table S14). Of the 2405 samples of dried-blood spots that were collected, TFV-DP levels were detectable in 51 samples (2%) and reached effective levels in 5 (&lt;1%) (Tables S15 and S16). Overall, PrEP–PEP was detected during an estimated 2% of person-years of follow-up in the vaccine group and 3% of person-years in the placebo group.</div></section><section id="sec-2-5"><h3>Safety, Reactogenicity, and Death</h3><div role="paragraph">The incidence of inaccurate administration of vaccine or placebo was low, with errors occurring in 3 of 2704 participants in the vaccine group and in 2 of 2700 participants in the placebo group. In general, vaccinations were safe and had an acceptable side-effect profile, as reported by the participants (Tables S17, S18, and S19). Vaccine recipients were more likely than placebo recipients to report reactogenicity (46% vs. 33%, P&lt;0.001), with pain or tenderness at the injection site most frequently reported by vaccine recipients (23%) and headache reported most frequently by placebo recipients (16%). Most symptoms were mild. The number and frequency of adverse events were well balanced in the two groups (Table S20).</div><div role="paragraph">Adverse events that were deemed by investigators to be related to the injection were uncommon but were more frequent among the vaccine recipients than among the placebo recipients (1% vs. &lt;1%, P&lt;0.001). The few related adverse events that resulted in discontinuation included generalized rash (1 in the vaccine group and 2 in the placebo group), generalized urticaria or cellulitis (1 each in the vaccine group), and diarrhea or headache (1 each in the placebo group). Eighteen deaths, all deemed by the investigators to be unrelated to the trial agent, were reported in 8 vaccine recipients and in 10 placebo recipients. Details regarding deaths are provided in the Additional Safety Data and Analyses section in the <a href="#ap2">Supplementary Appendix</a>.</div></section><section id="sec-2-6"><h3>Pregnancy</h3><div role="paragraph">A total of 163 pregnancies were reported (82 in the vaccine group and 81 in the placebo group), which resulted in an annual pregnancy incidence of less than 3%. In 78 of these women (48%), oral hormonal contraception was the method last reported. No congenital anomalies were reported.</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">In the HVTN 702 trial, we found no significant effect of the vaccine regimen on the acquisition of HIV-1 infection in a well-powered evaluation involving 5404 participants. In an interim analysis performed in January 2020, the trial met the prespecified stopping criteria for nonefficacy with no safety concerns. At that time, the data and safety monitoring board recommended that vaccinations be stopped with unblinding of the results; all the participants were to be followed for 1 year after the last vaccination.</div><div role="paragraph">Several components of the vaccine regimen that we used in our trial differed from those used in the vaccine regimen of the earlier RV144 trial. These included the use of different vector vaccine gene-sequence inserts (the subtype C ZM96 strain of gp120, which was inserted into the HVTN 702 vector vaccine, as compared with the subtype CRF01_AE 92TH023 strain of gp120 that was inserted into the RV144 vector vaccine), a different protein vaccine sequence (subtype 1086 and TV1 strains, as compared with subtype CRF01_AE A244 and subtype B MN strains in RV144), the use of different adjuvants (MF59, as compared with aluminum hydroxide in RV114), and the use of additional booster injections in the HVTN 702 trial at 12 and 18 months.<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8 r9 r10" id="body-ref-r10" href-manipulated="true">8-10</a></sup> Differing patterns of immunogenicity have been seen in studies comparing the two regimens in South Africa. The HVTN 100 trial evaluated the immunogenicity of the regimen that we used in the HVTN 702 trial for comparison with the HVTN 097 trial, which evaluated the regimen used in the RV144 trial.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="body-ref-r11-1" href-manipulated="true" aria-label="Reference 11">11</a></sup> Levels of binding and functional antibodies to gp120 and gp140 antigens and T-cell responses to vaccine-matched peptide pools were greater with the HVTN 702 regimen (as assessed in the HVTN 100 trial) than with the RV114 regimen (as assessed in both the RV114 trial and the HVTN 097 trial).<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11 r12 r13" id="body-ref-r13" href-manipulated="true">11-13</a></sup> However, antibody responses in the V2 region were higher with the RV144 regimen than with the subtype C vaccine regimen.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="body-ref-r11-3" href-manipulated="true" aria-label="Reference 11">11</a></sup> The V2 region responses were important correlates of risk in the RV144 trial.<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12" id="body-ref-r12-2" href-manipulated="true" aria-label="Reference 12">12</a></sup> The substantial differences in antibody specificities induced by vaccination in these two regimens suggest that viral sequences or adjuvants may influence the elicitation of V2-specific antibodies, with higher values associated with decreased HIV-1 risk.<sup><a href="#core-r14" role="doc-biblioref" data-xml-rid="r14" id="body-ref-r14" href-manipulated="true" aria-label="Reference 14">14</a></sup></div><div role="paragraph">The incidence of HIV-1 acquisition (and thus potentially of HIV-1 exposure) was markedly higher in our trial than in the RV144 trial. Given the high prevalence of sexually transmitted infections among the women in our trial, it is likely that genital tract inflammation was also prevalent.<sup><a href="#core-r15" role="doc-biblioref" data-xml-rid="r15" id="body-ref-r15" href-manipulated="true" aria-label="Reference 15">15</a></sup> The HIV-1 incidence of 4.2% among the women in the placebo group in our trial was 14 times that seen among women in the placebo group in the RV144 trial (0.3%). This incidence reflects hyperendemic HIV-1 transmission in the community, probably from the high frequency of acute infections and low rates of viral suppression.<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16" id="body-ref-r16" href-manipulated="true" aria-label="Reference 16">16</a></sup> In the RV144 trial, a lower vaccine efficacy was observed among participants at high risk for HIV-1 acquisition than among those at low or moderate risk.<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17" id="body-ref-r17" href-manipulated="true" aria-label="Reference 17">17</a></sup> In nonhuman primates that were vaccinated with ALVAC–gp120, better protection from experimental mucosal infection was achieved with exposure to a low viral dose than with a high-dose challenge,<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18" id="body-ref-r18" href-manipulated="true" aria-label="Reference 18">18</a></sup> which provides a possible explanation for the role that the force of infection (i.e., the level of infectiousness, as defined by the amount of exposure to persons with viremia) plays in overcoming vaccine-induced immunity. We did not find vaccine efficacy in any subgroup, even among the participants who were determined to have a low risk of HIV-1 acquisition on the basis of the diagnosis of sexually transmitted infections and behavioral data. However, the eligibility criteria and high burden of HIV-1 infection in South Africa would suggest that few women who were actually at low risk were enrolled in the trial.</div><div role="paragraph">The genetic diversity of the sub-Saharan African subtype C epidemic was substantially greater than that in the epidemic of HIV subtype A/E in Thailand 15 years earlier, when the RV144 trial was conducted, a factor that is also likely to have played a role in the differential efficacy between the two trials. The vaccine efficacy in the RV144 trial was found to depend on viral genetics, especially with respect to whether the exposing HIV-1 strain matched the vaccine insert at amino acid position 169 (which was lysine) in the V2 loop.<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19" id="body-ref-r19" href-manipulated="true" aria-label="Reference 19">19</a></sup> Studies suggest that the frequency of such a match to the HVTN 702 vaccine is much less common in South Africa than in Thailand.<sup><a href="#core-r20" role="doc-biblioref" data-xml-rid="r20" id="body-ref-r20" href-manipulated="true" aria-label="Reference 20">20</a></sup> The match of the V1V2 region of the HVTN 702 vaccine components with circulating sequences in South Africa, as compared with their Thai counterparts in the RV144 trial, is also less common on the basis of HIV-1 sequencing data from the Los Alamos National Laboratory database<sup><a href="#core-r21" role="doc-biblioref" data-xml-rid="r21" id="body-ref-r21" href-manipulated="true" aria-label="Reference 21">21</a></sup> (Fig. S12).</div><div role="paragraph">In addition, host genetic factors that may influence vaccine efficacy also differ between the South African and Thai populations. Data from the RV144 trial suggest that vaccine efficacy depends on the presence or absence of <i>FCGR2C</i> and the HLA-A*02 genotype.<sup><a href="#core-r22" role="doc-biblioref" data-xml-rid="r22 r23 r24" id="body-ref-r24" href-manipulated="true">22-24</a></sup> Recent data suggest that South Africa has a relatively low prevalence of genotypes of the fragment crystallizable region (the portion of an antibody that is involved in immune activation) and human leukocyte antigen class I that were associated with the high vaccine efficacy in the RV144 trial (Table S21).<sup><a href="#core-r25" role="doc-biblioref" data-xml-rid="r25 r26 r27" id="body-ref-r27" href-manipulated="true">25-27</a></sup></div><div role="paragraph">Limitations of our trial include the inability to directly compare the regimens used in the RV144 and HVTN 702 trials to address differences in the use of vectors, adjuvants, and proteins. The absence of an available immunologic biomarker to predict protection further compounds our inability to infer whether differences in efficacy are explained by observed differences in immunogenicity or by other factors, such as infection force and viral diversity. Additional studies on the immunologic characteristics and viral sequences are under way to improve our understanding of the results and implications for this field of research. Thus, isolating which factor or combination of factors is responsible for the different efficacy results in the two trials will be challenging, given the differences between the vaccines and the immune responses they generated, along with the differences in the levels of viral exposure, the extent of matching between the vaccines and the exposing viruses, and in host genetics and other host factors.</div><div role="paragraph">Despite promising immunogenicity, this canarypox–protein HIV vaccine regimen was not efficacious in preventing the acquisition of HIV-1 infection in our trial population in South Africa. The high HIV-1 incidence that we observed in our trial illustrates the unrelenting aspect of the epidemic, especially among young women. More than ever, an effective vaccine to prevent HIV-1 acquisition in diverse populations is needed.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="disclaimer" role="paragraph">The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, or the Gates Foundation. GlaxoSmithKline Biologicals was provided the opportunity to review a preliminary version of this manuscript for factual accuracy, but the authors are solely responsible for final content and interpretation.</div><div data-type="version-of-record" role="paragraph">This is the <i>New England Journal of Medicine</i> version of record, which includes all <i>Journal</i> editing and enhancements. The Author Final Manuscript, which is the author’s version after external peer review and before publication in the <i>Journal</i>, is available under a CC BY license at <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888373/" target="_blank">PMC7888373</a>.</div><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by grants (HHSN272201300033C and HHSN272201600012C) to Novartis Vaccines and Diagnostics (now part of the <span class="named-content" data-type="funder">GlaxoSmithKline</span> [GSK] Biologicals) by the <span class="named-content" data-type="funder">National Institute of Allergy and Infectious Diseases</span> (NIAID) of the National Institutes of Health (NIH) for the selection and process development of the two gp120 envelope proteins TV1.C and 1086.C; by the <span class="named-content" data-type="funder">Bill and Melinda Gates Foundation</span> Global Health Grant (OPP1017604) and NIAID for the manufacture and release of the gp120 clinical grade material; and by U.S. Public Health Service Grants — UM1 AI068614 to the HIV Vaccine Trials Network (HVTN), UM1 AI068635 to the HVTN Statistical and Data Management Center, and UM1 AI068618 to the HVTN Laboratory Center — from the NIAID. GSK Biologicals contributed financially to the provision of preexposure prophylaxis to trial participants. The <span class="named-content" data-type="funder">South African Medical Research Council</span> supported its affiliated research sites.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank the trial participants and staff members; members of the trial-site community and the HVTN core staff; the staff members of the Hutchinson Centre Research Institute of South Africa, the Statistical Center for HIV–AIDS Research and Prevention, the HVTN Laboratory Center, the Vaccine Research Program of the Division of AIDS of the NIH and the NIAID, and the Pharmaceutical Affairs Branch; Triclinium Clinical Development; and the P5 partners, including Sanofi Pasteur, GSK, the Bill and Melinda Gates Foundation, the NIAID, the NIH, the U.S. Military HIV Research Program, and the South African Medical Research Council; Nina Russell and Margaret Johnston of the Bill and Melinda Gates Foundation for their counsel; Michael Pensiero of the NIAID for oversight on product development; Jacqueline Odhiambo for her ongoing project-management support; and Ashley Clayton and Mindy Miner for their assistance with manuscript development and technical editing. This article is dedicated to the memory of our regional medical liaison, Keitumetse Diphoko.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap0" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Research Summary</span> <span class="core-filename">(nejmoa2031499_research-summary.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2031499/suppl_file/nejmoa2031499_research-summary.pdf" download="nejmoa2031499_research-summary.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2031499_research-summary.pdf" data-doi="10.1056/NEJMoa2031499">Download</a></li><li>216.29 KB</li></ul></div></div><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2031499_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2031499/suppl_file/nejmoa2031499_protocol.pdf" download="nejmoa2031499_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2031499_protocol.pdf" data-doi="10.1056/NEJMoa2031499">Download</a></li><li>6.90 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2031499_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2031499/suppl_file/nejmoa2031499_appendix.pdf" download="nejmoa2031499_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2031499_appendix.pdf" data-doi="10.1056/NEJMoa2031499">Download</a></li><li>987.92 KB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2031499_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2031499/suppl_file/nejmoa2031499_disclosures.pdf" download="nejmoa2031499_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2031499_disclosures.pdf" data-doi="10.1056/NEJMoa2031499">Download</a></li><li>1.08 MB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2031499_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2031499/suppl_file/nejmoa2031499_data-sharing.pdf" download="nejmoa2031499_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2031499_data-sharing.pdf" data-doi="10.1056/NEJMoa2031499">Download</a></li><li>69.53 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content"><em>UNAIDS data 2018</em>. Geneva: UNAIDS, July 2018 (<a href="https://www.unaids.org/en/resources/documents/2018/unaids-data-2018">https://www.unaids.org/en/resources/documents/2018/unaids-data-2018</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=UNAIDS+data+2018&amp;publication_year=2018" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Simbayi L, Zuma KK, Zungu NP, et al. <em>South African national HIV prevalence, incidence, behaviour and communication survey, 2017: HIV impact assessment summary report</em>. Cape Town, South Africa: Human Sciences Research Council, October 2019.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=South+African+national+HIV+prevalence%2C+incidence%2C+behaviour+and+communication+survey%2C+2017%3A+HIV+impact+assessment+summary+report&amp;publication_year=2019" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. <em>N Engl J Med</em> 2009;361:2209-2220.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_4_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2031499&amp;key=10.1056%2FNEJMoa0908492&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19843557/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000272257100004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Vaccination+with+ALVAC+and+AIDSVAX+to+prevent+HIV-1+infection+in+Thailand.&amp;publication_year=2009&amp;journal=N+Engl+J+Med&amp;pages=2209-2220&amp;doi=10.1056%2FNEJMoa0908492&amp;pmid=19843557" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Gray G, Doherty T, Mohapi L, et al. HIV research in South Africa: advancing life. <em>S Afr Med J</em> 2019;109:36-40.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.7196/SAMJ.2019.v109i11b.14264" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32252866/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=HIV+research+in+South+Africa%3A+advancing+life.&amp;publication_year=2019&amp;journal=S+Afr+Med+J&amp;pages=36-40&amp;doi=10.7196%2FSAMJ.2019.v109i11b.14264&amp;pmid=32252866" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Laher F, Moodie Z, Cohen KW, et al. Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: a randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. <em>PLoS Med</em> 2020;17(2):e1003038-e1003038.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pmed.1003038" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32092060/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000558128100011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+immune+responses+after+a+12-month+booster+in+healthy+HIV-uninfected+adults+in+HVTN+100+in+South+Africa%3A+a+randomized+double-blind+placebo-controlled+trial+of+ALVAC-HIV+%28vCP2438%29+and+bivalent+subtype+C+gp120%2FMF59+vaccines.&amp;publication_year=2020&amp;journal=PLoS+Med&amp;pages=e1003038-e1003038&amp;doi=10.1371%2Fjournal.pmed.1003038&amp;pmid=32092060" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Gilbert PB, Grove D, Gabriel E, et al. A sequential phase 2b trial design for evaluating vaccine efficacy and immune correlates for multiple HIV vaccine regimens. <em>Stat Commun Infect Dis</em> 2011;3:1037-1037.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23181167/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+sequential+phase+2b+trial+design+for+evaluating+vaccine+efficacy+and+immune+correlates+for+multiple+HIV+vaccine+regimens.&amp;publication_year=2011&amp;journal=Stat+Commun+Infect+Dis&amp;pages=1037-1037&amp;pmid=23181167" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Holm S. A simple sequentially rejective multiple test procedure. <em>Scand J Stat</em> 1979;6:65-70.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1979JY78700003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+simple+sequentially+rejective+multiple+test+procedure.&amp;publication_year=1979&amp;journal=Scand+J+Stat&amp;pages=65-70" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">O’Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. <em>Expert Rev Vaccines</em> 2007;6:699-710.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1586/14760584.6.5.699" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17931151/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000250656300015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=MF59+is+a+safe+and+potent+vaccine+adjuvant+that+enhances+protection+against+influenza+virus+infection.&amp;publication_year=2007&amp;journal=Expert+Rev+Vaccines&amp;pages=699-710&amp;doi=10.1586%2F14760584.6.5.699&amp;pmid=17931151" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">O’Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59 — an innately attractive adjuvant formulation. <em>Vaccine</em> 2012;30:4341-4348.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.vaccine.2011.09.061" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22682289/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000306299200009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+mechanism+of+action+of+MF59+%E2%80%94+an+innately+attractive+adjuvant+formulation.&amp;publication_year=2012&amp;journal=Vaccine&amp;pages=4341-4348&amp;doi=10.1016%2Fj.vaccine.2011.09.061&amp;pmid=22682289" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Shen X, Laher F, Moodie Z, et al. HIV-1 vaccine sequences impact V1V2 antibody responses: a comparison of two poxvirus prime gp120 boost vaccine regimens. <em>Sci Rep</em> 2020;10:2093-2093.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41598-020-57491-z" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32034163/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000562828300010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=HIV-1+vaccine+sequences+impact+V1V2+antibody+responses%3A+a+comparison+of+two+poxvirus+prime+gp120+boost+vaccine+regimens.&amp;publication_year=2020&amp;journal=Sci+Rep&amp;pages=2093-2093&amp;doi=10.1038%2Fs41598-020-57491-z&amp;pmid=32034163" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Bekker L-G, Moodie Z, Grunenberg N, et al. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. <em>Lancet HIV</em> 2018;5(7):e366-e378.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r11" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2352-3018(18)30071-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29898870/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000437674000016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Subtype+C+ALVAC-HIV+and+bivalent+subtype+C+gp120%2FMF59+HIV-1+vaccine+in+low-risk%2C+HIV-uninfected%2C+South+African+adults%3A+a+phase+1%2F2+trial.&amp;publication_year=2018&amp;journal=Lancet+HIV&amp;pages=e366-e378&amp;doi=10.1016%2FS2352-3018%2818%2930071-7&amp;pmid=29898870" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r11" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r11-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] the regimen used in the RV144 trial. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r13" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] the RV114 trial and the HVTN 097 trial). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] than with the subtype C vaccine regimen. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Gottardo R, Bailer RT, Korber BT, et al. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. <em>PLoS One</em> 2013;8(9):e75665-e75665.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r12" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pone.0075665" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24086607/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000325220000034" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Plasma+IgG+to+linear+epitopes+in+the+V2+and+V3+regions+of+HIV-1+gp120+correlate+with+a+reduced+risk+of+infection+in+the+RV144+vaccine+efficacy+trial.&amp;publication_year=2013&amp;journal=PLoS+One&amp;pages=e75665-e75665&amp;doi=10.1371%2Fjournal.pone.0075665&amp;pmid=24086607" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r12" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r13" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] the RV114 trial and the HVTN 097 trial). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] correlates of risk in the RV144 trial. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Gray GE, Huang Y, Grunenberg N, et al. Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. <em>Sci Transl Med</em> 2019;11:eaax1880-eaax1880.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/scitranslmed.aax1880" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31534016/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000486430400005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Immune+correlates+of+the+Thai+RV144+HIV+vaccine+regimen+in+South+Africa.&amp;publication_year=2019&amp;journal=Sci+Transl+Med&amp;pages=eaax1880-eaax1880&amp;doi=10.1126%2Fscitranslmed.aax1880&amp;pmid=31534016" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. <em>N Engl J Med</em> 2012;366:1275-1286.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_15_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2031499&amp;key=10.1056%2FNEJMoa1113425&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22475592/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000302343000005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Immune-correlates+analysis+of+an+HIV-1+vaccine+efficacy+trial.&amp;publication_year=2012&amp;journal=N+Engl+J+Med&amp;pages=1275-1286&amp;doi=10.1056%2FNEJMoa1113425&amp;pmid=22475592" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Passmore J-AS, Jaspan HB, Masson L. Genital inflammation, immune activation and risk of sexual HIV acquisition. <em>Curr Opin HIV AIDS</em> 2016;11:156-162.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/COH.0000000000000232" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26628324/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000369652400005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Genital+inflammation%2C+immune+activation+and+risk+of+sexual+HIV+acquisition.&amp;publication_year=2016&amp;journal=Curr+Opin+HIV+AIDS&amp;pages=156-162&amp;doi=10.1097%2FCOH.0000000000000232&amp;pmid=26628324" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Powers KA, Ghani AC, Miller WC, et al. The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. <em>Lancet</em> 2011;378:256-268.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(11)60842-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21684591/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000293201100033" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+role+of+acute+and+early+HIV+infection+in+the+spread+of+HIV+and+implications+for+transmission+prevention+strategies+in+Lilongwe%2C+Malawi%3A+a+modelling+study.&amp;publication_year=2011&amp;journal=Lancet&amp;pages=256-268&amp;doi=10.1016%2FS0140-6736%2811%2960842-8&amp;pmid=21684591" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Robb ML, Rerks-Ngarm S, Nitayaphan S, et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. <em>Lancet Infect Dis</em> 2012;12:531-537.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1473-3099(12)70088-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22652344/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000306045300026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Risk+behaviour+and+time+as+covariates+for+efficacy+of+the+HIV+vaccine+regimen+ALVAC-HIV+%28vCP1521%29+and+AIDSVAX+B%2FE%3A+a+post-hoc+analysis+of+the+Thai+phase+3+efficacy+trial+RV+144.&amp;publication_year=2012&amp;journal=Lancet+Infect+Dis&amp;pages=531-537&amp;doi=10.1016%2FS1473-3099%2812%2970088-9&amp;pmid=22652344" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Vaccari M, Keele BF, Bosinger SE, et al. Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure. <em>J Virol</em> 2013;87:3538-3548.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1128/JVI.02863-12" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23325681/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000315348500050" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Protection+afforded+by+an+HIV+vaccine+candidate+in+macaques+depends+on+the+dose+of+SIVmac251+at+challenge+exposure.&amp;publication_year=2013&amp;journal=J+Virol&amp;pages=3538-3548&amp;doi=10.1128%2FJVI.02863-12&amp;pmid=23325681" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Rolland M, Edlefsen PT, Larsen BB, et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. <em>Nature</em> 2012;490:417-420.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature11519" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22960785/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000309918500049" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Increased+HIV-1+vaccine+efficacy+against+viruses+with+genetic+signatures+in+Env+V2.&amp;publication_year=2012&amp;journal=Nature&amp;pages=417-420&amp;doi=10.1038%2Fnature11519&amp;pmid=22960785" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Rademeyer C, Korber B, Seaman MS, et al. Features of recently transmitted HIV-1 clade C viruses that impact antibody recognition: implications for active and passive immunization. <em>PLoS Pathog</em> 2016;12(7):e1005742-e1005742.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.ppat.1005742" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27434311/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000383366400027" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Features+of+recently+transmitted+HIV-1+clade+C+viruses+that+impact+antibody+recognition%3A+implications+for+active+and+passive+immunization.&amp;publication_year=2016&amp;journal=PLoS+Pathog&amp;pages=e1005742-e1005742&amp;doi=10.1371%2Fjournal.ppat.1005742&amp;pmid=27434311" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Los Alamos National Laboratory. <em>HIV databases</em> (<a href="http://www.hiv.lanl.gov/">http://www.hiv.lanl.gov/</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=HIV+databases" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Li SS, Gilbert PB, Tomaras GD, et al. FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. <em>J Clin Invest</em> 2014;124:3879-3890.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1172/JCI75539" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25105367/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000341168100023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=FCGR2C+polymorphisms+associate+with+HIV-1+vaccine+protection+in+RV144+trial.&amp;publication_year=2014&amp;journal=J+Clin+Invest&amp;pages=3879-3890&amp;doi=10.1172%2FJCI75539&amp;pmid=25105367" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Gartland AJ, Li S, McNevin J, et al. Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial. <em>J Virol</em> 2014;88:8242-8255.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1128/JVI.01164-14" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24829343/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000338924400005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Analysis+of+HLA+A%2A02+association+with+vaccine+efficacy+in+the+RV144+HIV-1+vaccine+trial.&amp;publication_year=2014&amp;journal=J+Virol&amp;pages=8242-8255&amp;doi=10.1128%2FJVI.01164-14&amp;pmid=24829343" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Prentice HA, Tomaras GD, Geraghty DE, et al. HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition. <em>Sci Transl Med</em> 2015;7:296ra112-296ra112.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/scitranslmed.aab4005" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26180102/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000358738400005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=HLA+class+II+genes+modulate+vaccine-induced+antibody+responses+to+affect+HIV-1+acquisition.&amp;publication_year=2015&amp;journal=Sci+Transl+Med&amp;pages=296ra112-296ra112&amp;doi=10.1126%2Fscitranslmed.aab4005&amp;pmid=26180102" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Lassaunière R, Tiemessen CT. Variability at the FCGR locus: characterization in Black South Africans and evidence for ethnic variation in and out of Africa. <em>Genes Immun</em> 2016;17:93-104.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/gene.2015.60" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26673965/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000371902100003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Variability+at+the+FCGR+locus%3A+characterization+in+Black+South+Africans+and+evidence+for+ethnic+variation+in+and+out+of+Africa.&amp;publication_year=2016&amp;journal=Genes+Immun&amp;pages=93-104&amp;doi=10.1038%2Fgene.2015.60&amp;pmid=26673965" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">Hertz T, Logan MG, Rolland M, et al. A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trial. <em>Vaccine</em> 2016;34:5792-5801.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.vaccine.2016.09.054" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27756485/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000387196800014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+study+of+vaccine-induced+immune+pressure+on+breakthrough+infections+in+the+Phambili+phase+2b+HIV-1+vaccine+efficacy+trial.&amp;publication_year=2016&amp;journal=Vaccine&amp;pages=5792-5801&amp;doi=10.1016%2Fj.vaccine.2016.09.054&amp;pmid=27756485" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="r27" class="citations"><div class="citation"><div class="citation-content">Tshabalala M, Mellet J, Pepper MS. Human leukocyte antigen diversity: a southern African perspective. <em>J Immunol Res</em> 2015;2015:746151-746151.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1155/2015/746151" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26347896/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000360164900001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Human+leukocyte+antigen+diversity%3A+a+southern+African+perspective.&amp;publication_year=2015&amp;journal=J+Immunol+Res&amp;pages=746151-746151&amp;doi=10.1155%2F2015%2F746151&amp;pmid=26347896" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/384/12"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">384</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">12</span></span> • <span property="datePublished">March 25, 2021</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">1089</span>-<span property="pageEnd">1100</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2021 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: March 24, 2021</div><div><b class="core-label">Published in issue</b>: March 25, 2021</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/global-health" alt="View article keyword Global Health" data-interactiontype="article_recirculation_click">Global Health</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/hiv-aids" alt="View article keyword HIV/AIDS" data-interactiontype="article_recirculation_click">HIV/AIDS</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/vaccines" alt="View article keyword Vaccines" data-interactiontype="article_recirculation_click">Vaccines</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Glenda E.</span> <span property="familyName">Gray</span>, <span property="honorificSuffix">M.B., B.Ch.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-4649-1477" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-4649-1477</a></span>, <span property="author" typeof="Person"><span property="givenName">Linda-Gail</span> <span property="familyName">Bekker</span>, <span property="honorificSuffix">M.B., Ch.B., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Fatima</span> <span property="familyName">Laher</span>, <span property="honorificSuffix">M.B., B.Ch.</span></span>, <span property="author" typeof="Person"><span property="givenName">Mookho</span> <span property="familyName">Malahleha</span>, <span property="honorificSuffix">M.B., Ch.B., M.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Mary</span> <span property="familyName">Allen</span>, <span property="honorificSuffix">B.S.N., M.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Zoe</span> <span property="familyName">Moodie</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Nicole</span> <span property="familyName">Grunenberg</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Yunda</span> <span property="familyName">Huang</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Doug</span> <span property="familyName">Grove</span>, <span property="honorificSuffix">M.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Brittany</span> <span property="familyName">Prigmore</span>, <span property="honorificSuffix">M.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jia J.</span> <span property="familyName">Kee</span>, <span property="honorificSuffix">M.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">David</span> <span property="familyName">Benkeser</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">John</span> <span property="familyName">Hural</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Craig</span> <span property="familyName">Innes</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span>, <span property="author" typeof="Person"><span property="givenName">Erica</span> <span property="familyName">Lazarus</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span>, <span property="author" typeof="Person"><span property="givenName">Graeme</span> <span property="familyName">Meintjes</span>, <span property="honorificSuffix">M.B., Ch.B., M.P.H., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Nivashnee</span> <span property="familyName">Naicker</span>, <span property="honorificSuffix">M.B., Ch.B., M.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Dishiki</span> <span property="familyName">Kalonji</span>, <span property="honorificSuffix">M.B., B.Ch.</span></span>, <span property="author" typeof="Person"><span property="givenName">Maphoshane</span> <span property="familyName">Nchabeleng</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span>, <span property="author" typeof="Person"><span property="givenName">Modulakgotla</span> <span property="familyName">Sebe</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span>, <span property="author" typeof="Person"><span property="givenName">Nishanta</span> <span property="familyName">Singh</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span>, <span property="author" typeof="Person"><span property="givenName">Philip</span> <span property="familyName">Kotze</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sheetal</span> <span property="familyName">Kassim</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span>, <span property="author" typeof="Person"><span property="givenName">Thozama</span> <span property="familyName">Dubula</span>, <span property="honorificSuffix">M.Med.</span></span>, <span property="author" typeof="Person"><span property="givenName">Vimla</span> <span property="familyName">Naicker</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span>, <span property="author" typeof="Person"><span property="givenName">William</span> <span property="familyName">Brumskine</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span>, <span property="author" typeof="Person"><span property="givenName">Cleon N.</span> <span property="familyName">Ncayiya</span>, <span property="honorificSuffix">B.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Amy M.</span> <span property="familyName">Ward</span>, <span property="honorificSuffix">M.B., B.Ch.</span></span>, <span property="author" typeof="Person"><span property="givenName">Nigel</span> <span property="familyName">Garrett</span>, <span property="honorificSuffix">M.B., B.S., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Girisha</span> <span property="familyName">Kistnasami</span>, <span property="honorificSuffix">B.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Zakir</span> <span property="familyName">Gaffoor</span>, <span property="honorificSuffix">M.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Pearl</span> <span property="familyName">Selepe</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span>, <span property="author" typeof="Person"><span property="givenName">Philisiwe B.</span> <span property="familyName">Makhoba</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span>, <span property="author" typeof="Person"><span property="givenName">Matsontso P.</span> <span property="familyName">Mathebula</span>, <span property="honorificSuffix">M.B., Ch.B., M.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Pamela</span> <span property="familyName">Mda</span>, <span property="honorificSuffix">M.B., Ch.B., M.Med.</span></span>, <span property="author" typeof="Person"><span property="givenName">Tania</span> <span property="familyName">Adonis</span>, <span property="honorificSuffix">B.Psych.</span></span>, <span property="author" typeof="Person"><span property="givenName">Katlego S.</span> <span property="familyName">Mapetla</span>, <span property="honorificSuffix">B.Tech.</span></span>, <span property="author" typeof="Person"><span property="givenName">Bontle</span> <span property="familyName">Modibedi</span>, <span property="honorificSuffix">R.N.</span></span>, <span property="author" typeof="Person"><span property="givenName">Tricia</span> <span property="familyName">Philip</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span>, <span property="author" typeof="Person"><span property="givenName">Gladys</span> <span property="familyName">Kobane</span>, <span property="honorificSuffix">R.N.</span></span>, <span property="author" typeof="Person"><span property="givenName">Carter</span> <span property="familyName">Bentley</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Shelly</span> <span property="familyName">Ramirez</span>, <span property="honorificSuffix">M.A.</span></span>, <span property="author" typeof="Person"><span property="givenName">Simbarashe</span> <span property="familyName">Takuva</span>, <span property="honorificSuffix">M.B., Ch.B.</span> <a class="orcid-id" href="https://orcid.org/0000-0001-6030-2359" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0001-6030-2359</a></span>, <span property="author" typeof="Person"><span property="givenName">Megan</span> <span property="familyName">Jones</span>, <span property="honorificSuffix">B.S.N., M.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Mpho</span> <span property="familyName">Sikhosana</span>, <span property="honorificSuffix">M.B., B.Ch., M.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Millicent</span> <span property="familyName">Atujuna</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Michele</span> <span property="familyName">Andrasik</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Nima S.</span> <span property="familyName">Hejazi</span>, <span property="honorificSuffix">M.A.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-7127-2789" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-7127-2789</a></span>, <span property="author" typeof="Person"><span property="givenName">Adrian</span> <span property="familyName">Puren</span>, <span property="honorificSuffix">M.B., B.Ch., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Lubbe</span> <span property="familyName">Wiesner</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sanjay</span> <span property="familyName">Phogat</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Carlos</span> <span property="familyName">Diaz Granados</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Marguerite</span> <span property="familyName">Koutsoukos</span>, <span property="honorificSuffix">M.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Olivier</span> <span property="familyName">Van Der Meeren</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-0291-743X" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-0291-743X</a></span>, <span property="author" typeof="Person"><span property="givenName">Susan W.</span> <span property="familyName">Barnett</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Niranjan</span> <span property="familyName">Kanesa-Thasan</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">James G.</span> <span property="familyName">Kublin</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">M. Juliana</span> <span property="familyName">McElrath</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Peter B.</span> <span property="familyName">Gilbert</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Holly</span> <span property="familyName">Janes</span>, <span property="honorificSuffix">Ph.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Lawrence</span> <span property="familyName">Corey</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-2179-2436" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-2179-2436</a></span>, for <span property="author" typeof="Person">the HVTN 702 Study Team<sup><a href="#fn1" role="doc-noteref">*</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center (G.E.G., Z.M., N. Grunenberg, Y.H., D.G., B.P., J.J.K., J.H., C.B., S.R., S.T., M.J., M. Sikhosana, M. Andrasik, J.G.K., M.J.M., P.B.G., H.J., L.C.), Seattle; the Perinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand (G.E.G., F.L., E.L., B.M., T.P., S.T.), the National Institute for Communicable Diseases, National Health Laboratory Service (A.P.), and Aurum Institute (C.I., M. Sebe, W.B., P.S., T.A., G. Kobane), Johannesburg, Desmond Tutu HIV Centre (L.-G.B., S.K., C.N.N., M. Atujuna), the Department of Medicine, Wellcome Centre for Infectious Diseases Research in Africa, and Institute of Infectious Disease and Molecular Medicine (G.M., A.M.W.), and the Division of Clinical Pharmacology, Department of Medicine (L.W.), University of Cape Town, Cape Town, Setshaba Research Centre, Soshanguve (M.M., K.S.M.), Mecru Clinical Research Unit, Sefako Mkgatho Health Sciences University, Ga-Rankuwa (M.N., M.P.M.), Nelson Mandela Academic Clinical Research Unit and Department of Internal Medicine and Pharmacology, Walter Sisulu University, Mthatha (T.D., P.M.), the School of Health Systems and Public Health, Faculty of Health Sciences, University of Pretoria, Pretoria (S.T.), the South African Medical Research Council (G.E.G., D.K., N.S., V.N., G. Kistnasami, Z.G.) and the Centre for the AIDS Programme of Research in South Africa, University of KwaZulu–Natal (N.N., N. Garrett), Durban, and Qhakaza Mbokodo Research Clinic, Ladysmith (P.K., P.B.M.) — all in South Africa; the Vaccine Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (M. Allen), and GlaxoSmithKline Vaccines, Rockville (N.K.-T.) — both in Maryland; the Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta (D.B.); GSK Vaccines, Cambridge, MA (S.W.B.); Sanofi Pasteur, Swiftwater, PA (S.P., C.D.G.); GlaxoSmithKline, Siena, Italy (S.P.); GlaxoSmithKline, Wavre (M.K.), and GlaxoSmithKline, Rixensart (O.V.D.M.) — both in Belgium; and the Graduate Group in Biostatistics and the Center for Computational Biology, University of California, Berkeley (N.S.H.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. Gray at the South African Medical Research Council, Francie Van Ziyl Rd., Parow Valley, Tygerberg 7505, South Africa, or at <a href="mailto:glenda.gray@mrc.ac.za">glenda.gray@mrc.ac.za</a>.</div><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="fn1" role="paragraph">A complete list of HVTN 702 Study Team members is provided in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">180</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2031499" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="84ea52a4-f67b-4155-aca5-7e9b372270a1"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=102714770" style="display:inline-block;">
                <img alt="Article has an altmetric score of 250" src="https://badges.altmetric.com/?size=320&amp;score=250&amp;types=mbtttttf" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=102714770">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_84ea52a4-f67b-4155-aca5-7e9b372270a1" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=102714770&amp;tab=news">
          Picked up by <b>17</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=102714770&amp;tab=blogs">
          Blogged by <b>5</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=102714770&amp;tab=twitter">
          Posted by <b>153</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=102714770&amp;tab=facebook">
          On <b>3</b> Facebook pages
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>244</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d673c4956d77c0-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2031499"> <input type="hidden" name="downloadFileName" value="csp_384_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.384.issue-12%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2031499%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="180" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Yunda Huang, </li><li class="list-inline-item cited-by__entry__author">Lily Zhang, </li><li class="list-inline-item cited-by__entry__author">Maria P. Lemos, </li><li class="list-inline-item cited-by__entry__author">Rena D. Astronomo, </li><li class="list-inline-item cited-by__entry__author">Sandeep Narpala, </li><li class="list-inline-item cited-by__entry__author">Madhu Prabhakaran, </li><li class="list-inline-item cited-by__entry__author">Nina Marie G. Garcia, </li><li class="list-inline-item cited-by__entry__author">Yiwen Lu, </li><li class="list-inline-item cited-by__entry__author">Greg J. Mize, </li><li class="list-inline-item cited-by__entry__author">Hayley Glantz, </li><li class="list-inline-item cited-by__entry__author">Hunter Colegrove, </li><li class="list-inline-item cited-by__entry__author">Philipp Mann, </li><li class="list-inline-item cited-by__entry__author">Carmen A. Paez, </li><li class="list-inline-item cited-by__entry__author">Erica Andersen‐Nissen, </li><li class="list-inline-item cited-by__entry__author">Julia Hutter, </li><li class="list-inline-item cited-by__entry__author">Julie Dumond, </li><li class="list-inline-item cited-by__entry__author">Adrian B. McDermott, </li><li class="list-inline-item cited-by__entry__author">John R. Mascola, </li><li class="list-inline-item cited-by__entry__author">Richard A. Koup, </li><li class="list-inline-item cited-by__entry__author">Linda‐Gail Bekker, </li><li class="list-inline-item cited-by__entry__author">M. Juliana McElrath, </li></ul><span class="cited-by__entry__title">Pharmacokinetics Analysis of Serum and Rectal Tissue Concentrations of a Pair of Anti‐HIV Monoclonal Antibodies, VRC01 and VRC01LS, in Adults without HIV, </span><span class="cited-by__entry__series-title">The Journal of Clinical Pharmacology, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1002/jcph.70060" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1002/jcph.70060</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1002/jcph.70060" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Chama Chanda, </li><li class="list-inline-item cited-by__entry__author">Freddie Kibengo, </li><li class="list-inline-item cited-by__entry__author">Michael Mutua, </li><li class="list-inline-item cited-by__entry__author">Fred Ogada, </li><li class="list-inline-item cited-by__entry__author">Vincent Muturi-Kioi, </li><li class="list-inline-item cited-by__entry__author">Belkis M Akis Yildirim, </li><li class="list-inline-item cited-by__entry__author">Mary Amondi, </li><li class="list-inline-item cited-by__entry__author">Andrea Baines, </li><li class="list-inline-item cited-by__entry__author">Vincent Basajja, </li><li class="list-inline-item cited-by__entry__author">Nicola Borthwick, </li><li class="list-inline-item cited-by__entry__author">Kefa Bosire, </li><li class="list-inline-item cited-by__entry__author">Elias Chambula, </li><li class="list-inline-item cited-by__entry__author">Paramesh Chetty, </li><li class="list-inline-item cited-by__entry__author">Kundai Chinyenze, </li><li class="list-inline-item cited-by__entry__author">Oscar Chirro, </li><li class="list-inline-item cited-by__entry__author">Alison Crook, </li><li class="list-inline-item cited-by__entry__author">Jan De Bont, </li><li class="list-inline-item cited-by__entry__author">Natalia Fernandez, </li><li class="list-inline-item cited-by__entry__author">Peter Ejou, </li><li class="list-inline-item cited-by__entry__author">Bashir Farah, </li><li class="list-inline-item cited-by__entry__author">Molly Glaze, </li><li class="list-inline-item cited-by__entry__author">Ben Gombe, </li><li class="list-inline-item cited-by__entry__author">Anne Gumbe, </li><li class="list-inline-item cited-by__entry__author">Peter Hayes, </li><li class="list-inline-item cited-by__entry__author">Sally Itwi, </li><li class="list-inline-item cited-by__entry__author">Sheba Juma, </li><li class="list-inline-item cited-by__entry__author">Anita Kabarambi, </li><li class="list-inline-item cited-by__entry__author">Chishiba Kabengele, </li><li class="list-inline-item cited-by__entry__author">Paddy Kafeero, </li><li class="list-inline-item cited-by__entry__author">Ayoub Kakande, </li><li class="list-inline-item cited-by__entry__author">Jennifer Kanungi, </li><li class="list-inline-item cited-by__entry__author">William Kidega, </li><li class="list-inline-item cited-by__entry__author">Deborah King, </li><li class="list-inline-item cited-by__entry__author">Rose Mahira, </li><li class="list-inline-item cited-by__entry__author">Roselyn Malogo, </li><li class="list-inline-item cited-by__entry__author">Mabela Matsoso, </li><li class="list-inline-item cited-by__entry__author">Clive Michelo, </li><li class="list-inline-item cited-by__entry__author">Annie Moyo, </li><li class="list-inline-item cited-by__entry__author">Susan Mugaba, </li><li class="list-inline-item cited-by__entry__author">Irene Mugenya, </li><li class="list-inline-item cited-by__entry__author">Patrick Muhumuza, </li><li class="list-inline-item cited-by__entry__author">Yama F Mujadidi, </li><li class="list-inline-item cited-by__entry__author">Moses Muriuki, </li><li class="list-inline-item cited-by__entry__author">Vernon Musale, </li><li class="list-inline-item cited-by__entry__author">Gaudensia Mutua, </li><li class="list-inline-item cited-by__entry__author">Meya Muwowo, </li><li class="list-inline-item cited-by__entry__author">Fatima Mwale, </li><li class="list-inline-item cited-by__entry__author">Irene Mwangi, </li><li class="list-inline-item cited-by__entry__author">Maria Nakimbugwe, </li><li class="list-inline-item cited-by__entry__author">Angella Namuyanja, </li><li class="list-inline-item cited-by__entry__author">Eunice Nduati, </li><li class="list-inline-item cited-by__entry__author">Leslie Nielsen, </li><li class="list-inline-item cited-by__entry__author">Jaquelyn Nyange, </li><li class="list-inline-item cited-by__entry__author">Geofrey Oino, </li><li class="list-inline-item cited-by__entry__author">Brenda Okech, </li><li class="list-inline-item cited-by__entry__author">Gloria Omosa-Manyonyi, </li><li class="list-inline-item cited-by__entry__author">Dan Otieno, </li><li class="list-inline-item cited-by__entry__author">Shaun Palmer, </li><li class="list-inline-item cited-by__entry__author">Hilda Phiri, </li><li class="list-inline-item cited-by__entry__author">Kelly Ramko, </li><li class="list-inline-item cited-by__entry__author">Rachel L Rutishauser, </li><li class="list-inline-item cited-by__entry__author">Eddy Sayeed, </li><li class="list-inline-item cited-by__entry__author">Rose Sajabi, </li><li class="list-inline-item cited-by__entry__author">Jennifer Serwanga, </li><li class="list-inline-item cited-by__entry__author">Edmund G-T Wee, </li><li class="list-inline-item cited-by__entry__author">Claire Wenden, </li><li class="list-inline-item cited-by__entry__author">Paola Cicconi, </li><li class="list-inline-item cited-by__entry__author">Patricia Fast, </li><li class="list-inline-item cited-by__entry__author">Jill Gilmour, </li><li class="list-inline-item cited-by__entry__author">Walter Jaoko, </li><li class="list-inline-item cited-by__entry__author">Pontiano Kaleebu, </li><li class="list-inline-item cited-by__entry__author">William Kilembe, </li><li class="list-inline-item cited-by__entry__author">Hester Kuipers, </li><li class="list-inline-item cited-by__entry__author">Eduard J Sanders, </li><li class="list-inline-item cited-by__entry__author">Tomáš Hanke, </li></ul><span class="cited-by__entry__title">Safety and broad immunogenicity of HIVconsvX conserved mosaic candidate T-cell vaccines vectored by ChAdOx1 and MVA in HIV-CORE 006: a double-blind, randomised, placebo-controlled phase 1 trial in healthy adults living without HIV-1 in eastern and southern Africa, </span><span class="cited-by__entry__series-title">The Lancet Microbe, </span><span class="cited-by__entry__volume"><strong>6</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(101041), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.lanmic.2024.101041" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.lanmic.2024.101041</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.lanmic.2024.101041" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Aleksandra Partsuneva, </li><li class="list-inline-item cited-by__entry__author">Anna Gancheva, </li><li class="list-inline-item cited-by__entry__author">Reneta Dimitrova, </li><li class="list-inline-item cited-by__entry__author">Lyubomira Grigorova, </li><li class="list-inline-item cited-by__entry__author">Asya Kostadinova, </li><li class="list-inline-item cited-by__entry__author">Maria Nikolova, </li><li class="list-inline-item cited-by__entry__author">Radoslava Emilova, </li><li class="list-inline-item cited-by__entry__author">Nina Yancheva, </li><li class="list-inline-item cited-by__entry__author">Rusina Grozdeva, </li><li class="list-inline-item cited-by__entry__author">Ivailo Alexiev, </li></ul><span class="cited-by__entry__title">Distinct Molecular Epidemiology, Transmission Patterns, and Resistance Mutations of HIV-1 Subtypes A1, A6, and A7 in Bulgaria, </span><span class="cited-by__entry__series-title">Microorganisms, </span><span class="cited-by__entry__volume"><strong>13</strong>, </span><span class="cited-by__entry__issue">5, </span><span class="cited-by__entry__page-range">(1108), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3390/microorganisms13051108" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3390/microorganisms13051108</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3390/microorganisms13051108" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Li-Yun Lin, </li><li class="list-inline-item cited-by__entry__author">Thomas Ferte, </li><li class="list-inline-item cited-by__entry__author">Mkunde Chachage, </li><li class="list-inline-item cited-by__entry__author">Celso Casteano, </li><li class="list-inline-item cited-by__entry__author">Géraldine Laumond, </li><li class="list-inline-item cited-by__entry__author">Sylvie Schmidt, </li><li class="list-inline-item cited-by__entry__author">Ouria Tahar, </li><li class="list-inline-item cited-by__entry__author">Raphael Carapito, </li><li class="list-inline-item cited-by__entry__author">Linda-Gail Bekker, </li><li class="list-inline-item cited-by__entry__author">Gavin Churchyard, </li><li class="list-inline-item cited-by__entry__author">Michael Keefer, </li><li class="list-inline-item cited-by__entry__author">Zoe Moodie, </li><li class="list-inline-item cited-by__entry__author">Edna Viegas, </li><li class="list-inline-item cited-by__entry__author">Christof Geldmacher, </li><li class="list-inline-item cited-by__entry__author">Edouard Lhomme, </li><li class="list-inline-item cited-by__entry__author">Christiane Moog, </li></ul><span class="cited-by__entry__title">Deciphering HIV vaccine-induced antibody response according to ethnicity, </span><span class="cited-by__entry__series-title">AIDS, </span><span class="cited-by__entry__volume"><strong>39</strong>, </span><span class="cited-by__entry__issue">8, </span><span class="cited-by__entry__page-range">(957-963), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1097/QAD.0000000000004196" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1097/QAD.0000000000004196</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1097/QAD.0000000000004196" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Chenyu Si, </li><li class="list-inline-item cited-by__entry__author">Jiawen Bai, </li><li class="list-inline-item cited-by__entry__author">Yuqing Li, </li><li class="list-inline-item cited-by__entry__author">Yang Li, </li><li class="list-inline-item cited-by__entry__author">Yishi Liu, </li><li class="list-inline-item cited-by__entry__author">Xiaoman Zhou, </li><li class="list-inline-item cited-by__entry__author">Jie Shi, </li><li class="list-inline-item cited-by__entry__author">Hideki Nakanishi, </li><li class="list-inline-item cited-by__entry__author">Zijie Li, </li></ul><span class="cited-by__entry__title">Establishment of a Novel Platform for Developing Oral Vaccines Based on the Surface Display System of Yeast Spores, </span><span class="cited-by__entry__series-title">International Journal of Molecular Sciences, </span><span class="cited-by__entry__volume"><strong>26</strong>, </span><span class="cited-by__entry__issue">8, </span><span class="cited-by__entry__page-range">(3615), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3390/ijms26083615" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3390/ijms26083615</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3390/ijms26083615" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Leigh H. Fisher, </li><li class="list-inline-item cited-by__entry__author">Erica Lazarus, </li><li class="list-inline-item cited-by__entry__author">Chenchen Yu, </li><li class="list-inline-item cited-by__entry__author">Zoe Moodie, </li><li class="list-inline-item cited-by__entry__author">Daniel J. Stieh, </li><li class="list-inline-item cited-by__entry__author">Nicole Yates, </li><li class="list-inline-item cited-by__entry__author">Lu Zhang, </li><li class="list-inline-item cited-by__entry__author">Sheetal Sawant, </li><li class="list-inline-item cited-by__entry__author">Stephen C. De Rosa, </li><li class="list-inline-item cited-by__entry__author">Kristen W. Cohen, </li><li class="list-inline-item cited-by__entry__author">Daryl Morris, </li><li class="list-inline-item cited-by__entry__author">Shannon Grant, </li><li class="list-inline-item cited-by__entry__author">April Randhawa, </li><li class="list-inline-item cited-by__entry__author">Maurine D. Miner, </li><li class="list-inline-item cited-by__entry__author">Jenny Hendriks, </li><li class="list-inline-item cited-by__entry__author">Frank Wegmann, </li><li class="list-inline-item cited-by__entry__author">Katherine M. Gill, </li><li class="list-inline-item cited-by__entry__author">Fatima Laher, </li><li class="list-inline-item cited-by__entry__author">Linda-Gail Bekker, </li><li class="list-inline-item cited-by__entry__author">Glenda E. Gray, </li><li class="list-inline-item cited-by__entry__author">Lawrence Corey, </li><li class="list-inline-item cited-by__entry__author">M. Juliana McElrath, </li><li class="list-inline-item cited-by__entry__author">Troy Martin, </li><li class="list-inline-item cited-by__entry__author">Peter B. Gilbert, </li><li class="list-inline-item cited-by__entry__author">Georgia Tomaras, </li><li class="list-inline-item cited-by__entry__author">Stephen R. Walsh, </li><li class="list-inline-item cited-by__entry__author">Lindsey R. Baden, </li></ul><span class="cited-by__entry__title">ALVAC-prime and monomeric gp120 protein boost induces distinct HIV-1 specific humoral and cellular responses compared with adenovirus-prime and trimeric gp140 protein boost, </span><span class="cited-by__entry__series-title">PLOS Global Public Health, </span><span class="cited-by__entry__volume"><strong>5</strong>, </span><span class="cited-by__entry__issue">4, </span><span class="cited-by__entry__page-range">(e0004250), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1371/journal.pgph.0004250" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1371/journal.pgph.0004250</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1371/journal.pgph.0004250" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Zoe Moodie, </li><li class="list-inline-item cited-by__entry__author">Shuying Sue Li, </li><li class="list-inline-item cited-by__entry__author">Elena E. Giorgi, </li><li class="list-inline-item cited-by__entry__author">LaTonya D. Williams, </li><li class="list-inline-item cited-by__entry__author">One Dintwe, </li><li class="list-inline-item cited-by__entry__author">Lindsay N. Carpp, </li><li class="list-inline-item cited-by__entry__author">Shiyu Chen, </li><li class="list-inline-item cited-by__entry__author">Kelly E. Seaton, </li><li class="list-inline-item cited-by__entry__author">Sheetal S. Sawant, </li><li class="list-inline-item cited-by__entry__author">Lu Zhang, </li><li class="list-inline-item cited-by__entry__author">Jack Heptinstall, </li><li class="list-inline-item cited-by__entry__author">Shuying Liu, </li><li class="list-inline-item cited-by__entry__author">Nicole Grunenberg, </li><li class="list-inline-item cited-by__entry__author">Frank Tomaka, </li><li class="list-inline-item cited-by__entry__author">Supachai Rerks-Ngarm, </li><li class="list-inline-item cited-by__entry__author">Punnee Pitisuttithum, </li><li class="list-inline-item cited-by__entry__author">Sorachai Nitayaphan, </li><li class="list-inline-item cited-by__entry__author">Julie A. Ake, </li><li class="list-inline-item cited-by__entry__author">Sandhya Vasan, </li><li class="list-inline-item cited-by__entry__author">Giuseppe Pantaleo, </li><li class="list-inline-item cited-by__entry__author">Ian Frank, </li><li class="list-inline-item cited-by__entry__author">Lindsey R. Baden, </li><li class="list-inline-item cited-by__entry__author">Paul A. Goepfert, </li><li class="list-inline-item cited-by__entry__author">Michael Keefer, </li><li class="list-inline-item cited-by__entry__author">Mike Chirenje, </li><li class="list-inline-item cited-by__entry__author">Mina C. Hosseinipour, </li><li class="list-inline-item cited-by__entry__author">Kathryn Mngadi, </li><li class="list-inline-item cited-by__entry__author">Fatima Laher, </li><li class="list-inline-item cited-by__entry__author">Nigel Garrett, </li><li class="list-inline-item cited-by__entry__author">Linda-Gail Bekker, </li><li class="list-inline-item cited-by__entry__author">Stephen De Rosa, </li><li class="list-inline-item cited-by__entry__author">Erica Andersen-Nissen, </li><li class="list-inline-item cited-by__entry__author">James G. Kublin, </li><li class="list-inline-item cited-by__entry__author">Shan Lu, </li><li class="list-inline-item cited-by__entry__author">Peter B. Gilbert, </li><li class="list-inline-item cited-by__entry__author">Glenda E. Gray, </li><li class="list-inline-item cited-by__entry__author">Lawrence Corey, </li><li class="list-inline-item cited-by__entry__author">M. Juliana McElrath, </li><li class="list-inline-item cited-by__entry__author">Georgia D. Tomaras, </li></ul><span class="cited-by__entry__title">A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials, </span><span class="cited-by__entry__series-title">Emerging Microbes &amp; Infections, </span><span class="cited-by__entry__volume"><strong>14</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1080/22221751.2025.2485317" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1080/22221751.2025.2485317</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1080/22221751.2025.2485317" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Ivana Beesham, </li><li class="list-inline-item cited-by__entry__author">Manjeetha Jaggernath, </li><li class="list-inline-item cited-by__entry__author">Yolandie Kriel, </li><li class="list-inline-item cited-by__entry__author">Jiaying Hao, </li><li class="list-inline-item cited-by__entry__author">Patricia M. Smith, </li><li class="list-inline-item cited-by__entry__author">Jessica E. Haberer, </li><li class="list-inline-item cited-by__entry__author">Craig W. Hendrix, </li><li class="list-inline-item cited-by__entry__author">Christina Psaros, </li><li class="list-inline-item cited-by__entry__author">David R. Bangsberg, </li><li class="list-inline-item cited-by__entry__author">Jennifer A. Smit, </li><li class="list-inline-item cited-by__entry__author">Lynn T. Matthews, </li></ul><span class="cited-by__entry__title">Longitudinal Changes in Tenofovir and Tenofovir Diphosphate Concentrations Among Pregnant Women Using Oral PrEP for HIV Prevention: Findings From Durban, South Africa, </span><span class="cited-by__entry__series-title">JAIDS Journal of Acquired Immune Deficiency Syndromes, </span><span class="cited-by__entry__volume"><strong>98</strong>, </span><span class="cited-by__entry__issue">4, </span><span class="cited-by__entry__page-range">(357-362), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1097/QAI.0000000000003586" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1097/QAI.0000000000003586</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1097/QAI.0000000000003586" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Michael V. Bick, </li><li class="list-inline-item cited-by__entry__author">Eduard Puig, </li><li class="list-inline-item cited-by__entry__author">David Beauparlant, </li><li class="list-inline-item cited-by__entry__author">Rebecca Nedellec, </li><li class="list-inline-item cited-by__entry__author">Iszac Burton, </li><li class="list-inline-item cited-by__entry__author">Keihvan Ardaghi, </li><li class="list-inline-item cited-by__entry__author">Thea R. Zalunardo, </li><li class="list-inline-item cited-by__entry__author">Raiza Bastidas, </li><li class="list-inline-item cited-by__entry__author">Xuduo Li, </li><li class="list-inline-item cited-by__entry__author">Javier Guenaga, </li><li class="list-inline-item cited-by__entry__author">Wen-Hsin Lee, </li><li class="list-inline-item cited-by__entry__author">Richard Wyatt, </li><li class="list-inline-item cited-by__entry__author">Wenwen Zhu, </li><li class="list-inline-item cited-by__entry__author">Max Crispin, </li><li class="list-inline-item cited-by__entry__author">Gabriel Ozorowski, </li><li class="list-inline-item cited-by__entry__author">Andrew B. Ward, </li><li class="list-inline-item cited-by__entry__author">Dennis R. Burton, </li><li class="list-inline-item cited-by__entry__author">Lars Hangartner, </li></ul><span class="cited-by__entry__title">Molecular parameters governing antibody FcγR signaling and effector functions in the context of HIV envelope, </span><span class="cited-by__entry__series-title">Cell Reports, </span><span class="cited-by__entry__volume"><strong>44</strong>, </span><span class="cited-by__entry__issue">4, </span><span class="cited-by__entry__page-range">(115331), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.celrep.2025.115331" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.celrep.2025.115331</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.celrep.2025.115331" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Xiaozhou He, </li><li class="list-inline-item cited-by__entry__author">Danying Chen, </li><li class="list-inline-item cited-by__entry__author">Qi Ma, </li><li class="list-inline-item cited-by__entry__author">Yanzhe Hao, </li><li class="list-inline-item cited-by__entry__author">Hongxia Li, </li><li class="list-inline-item cited-by__entry__author">Xiaoguang Zhang, </li><li class="list-inline-item cited-by__entry__author">Yuxi Cao, </li><li class="list-inline-item cited-by__entry__author">Xia Feng, </li></ul><span class="cited-by__entry__title">Decade-Long Sustained Cellular Immunity Induced by Sequential and Repeated Vaccination with Four Heterologous HIV Vaccines in Rhesus Macaques, </span><span class="cited-by__entry__series-title">Vaccines, </span><span class="cited-by__entry__volume"><strong>13</strong>, </span><span class="cited-by__entry__issue">4, </span><span class="cited-by__entry__page-range">(338), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3390/vaccines13040338" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3390/vaccines13040338</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3390/vaccines13040338" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.384.issue-12%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2031499%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2031499" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2031499" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2031499.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f0"><figure class="graphic"><a class="open-in-viewer" href="#f0" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2031499_f0.jpg"><img src="/cms/10.1056/NEJMoa2031499/asset/2cd64952-8529-4ebb-b4c1-7cb0e8086e5f/assets/images/large/nejmoa2031499_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"></a><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f0"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2031499_f0.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2031499_f1.jpg"><img src="/cms/10.1056/NEJMoa2031499/asset/b81de1e2-3439-4d27-adc5-3d454a01dde3/assets/images/large/nejmoa2031499_f1.jpg" height="2663" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Kaplan–Meier Analysis of HIV-1 Infection in Three Cohorts.</div><div class="notes"><div role="doc-footnote">Shown are data for the cumulative incidence of human immunodeficiency virus type 1 (HIV-1) infection among the participants in the modified intention-to-treat cohort who were evaluated during the period from randomization to 24 months (primary analysis cohort) (Panel A), in the cohort of participants who were HIV-1–negative at month 6.5 and were at risk for subsequent HIV-1 infection (month 6.5 at-risk cohort) (Panel B), and in the modified intention-to-treat cohort during the period from randomization to month 36 (Panel C). The apparent uptick in the vaccine curve at month 36 is due to a single infection among the remaining 11 participants at risk. In each panel, the inset shows the same data on an expanded y axis; in Panel C, the vaccine curve at 36 months has been cut off at 10% for graphical presentation.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2031499_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2031499_f2.jpg"><img src="/cms/10.1056/NEJMoa2031499/asset/73300005-7fba-465d-90cd-3ea4655629a2/assets/images/large/nejmoa2031499_f2.jpg" height="3076" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Kaplan–Meier Analysis of HIV-1 Infection, According to Sex and Women’s Age.</div><div class="notes"><div role="doc-footnote">Shown is the cumulative incidence of HIV-1 infection in the modified intention-to-treat cohort during the period from randomization to 24 months, according to two prespecified baseline variables: sex (Panel A) and women’s age (Panel B). In each panel, the inset shows the same data on an expanded y axis.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2031499_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2031499_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2031499/asset/0e2f6395-5b0b-4cd6-b251-c8c0023eb55f/assets/images/large/nejmoa2031499_t1.jpg" height="2361" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders" colspan="3"><span>Women</span></th><th class="txxr-borders" colspan="3"><span>Men</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Total<br>(N=3786)</th><th class="xxxx-borders">Vaccine<br>(N=1893)</th><th class="xxxx-borders">Placebo<br>(N=1893)</th><th class="xxxx-borders">Total<br>(N=1618)</th><th class="xxxx-borders">Vaccine<br>(N=811)</th><th class="xxxr-borders">Placebo<br>(N=807)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading">Age group — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">18–21 yr</td><td class="xxxx-borders">1115 (29)</td><td class="xxxx-borders">543 (29)</td><td class="xxxx-borders">572 (30)</td><td class="xxxx-borders">321 (20)</td><td class="xxxx-borders">166 (20)</td><td class="xxxr-borders">155 (19)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">22–25 yr</td><td class="xxxx-borders shading">1420 (38)</td><td class="xxxx-borders shading">723 (38)</td><td class="xxxx-borders shading">697 (37)</td><td class="xxxx-borders shading">438 (27)</td><td class="xxxx-borders shading">219 (27)</td><td class="xxxr-borders shading">219 (27)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">26–35 yr</td><td class="xxxx-borders">1251 (33)</td><td class="xxxx-borders">627 (33)</td><td class="xxxx-borders">624 (33)</td><td class="xxxx-borders">859 (53)</td><td class="xxxx-borders">426 (53)</td><td class="xxxr-borders">433 (54)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Body-mass index — no. (%)<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">&lt;18.5</td><td class="xxxx-borders">133 (4)</td><td class="xxxx-borders">56 (3)</td><td class="xxxx-borders">77 (4)</td><td class="xxxx-borders">232 (14)</td><td class="xxxx-borders">114 (14)</td><td class="xxxr-borders">118 (15)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">18.5–24</td><td class="xxxx-borders shading">1406 (37)</td><td class="xxxx-borders shading">725 (38)</td><td class="xxxx-borders shading">681 (36)</td><td class="xxxx-borders shading">1127 (70)</td><td class="xxxx-borders shading">560 (69)</td><td class="xxxr-borders shading">567 (70)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">25–29</td><td class="xxxx-borders">978 (26)</td><td class="xxxx-borders">493 (26)</td><td class="xxxx-borders">485 (26)</td><td class="xxxx-borders">194 (12)</td><td class="xxxx-borders">97 (12)</td><td class="xxxr-borders">97 (12)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">≥30</td><td class="xxxx-borders shading">1269 (34)</td><td class="xxxx-borders shading">619 (33)</td><td class="xxxx-borders shading">650 (34)</td><td class="xxxx-borders shading">65 (4)</td><td class="xxxx-borders shading">40 (5)</td><td class="xxxr-borders shading">25 (3)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Gender identity — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Female</td><td class="xxxx-borders shading">3783 (100)</td><td class="xxxx-borders shading">1892 (100)</td><td class="xxxx-borders shading">1891 (100)</td><td class="xxxx-borders shading">6 (&lt;1)</td><td class="xxxx-borders shading">5 (1)</td><td class="xxxr-borders shading">1 (&lt;1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Male</td><td class="xxxx-borders">2 (&lt;1)</td><td class="xxxx-borders">1 (&lt;1)</td><td class="xxxx-borders">1 (&lt;1)</td><td class="xxxx-borders">1598 (99)</td><td class="xxxx-borders">801 (99)</td><td class="xxxr-borders">797 (99)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Transgender female or male</td><td class="xxxx-borders shading">1 (&lt;1)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (&lt;1)</td><td class="xxxx-borders shading">10 (1)</td><td class="xxxx-borders shading">4 (&lt;1)</td><td class="xxxr-borders shading">6 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Gender variant</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">2 (&lt;1)</td><td class="xxxx-borders">1 (&lt;1)</td><td class="xxxr-borders">1 (&lt;1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Prefer not to answer</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (&lt;1)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">2 (&lt;1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Condom use — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Always</td><td class="xxxx-borders shading">209 (6)</td><td class="xxxx-borders shading">88 (5)</td><td class="xxxx-borders shading">121 (6)</td><td class="xxxx-borders shading">140 (9)</td><td class="xxxx-borders shading">79 (10)</td><td class="xxxr-borders shading">61 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Sometimes</td><td class="xxxx-borders">2790 (74)</td><td class="xxxx-borders">1411 (75)</td><td class="xxxx-borders">1379 (73)</td><td class="xxxx-borders">1228 (76)</td><td class="xxxx-borders">601 (74)</td><td class="xxxr-borders">627 (78)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Never</td><td class="xxxx-borders shading">786 (21)</td><td class="xxxx-borders shading">393 (21)</td><td class="xxxx-borders shading">393 (21)</td><td class="xxxx-borders shading">249 (15)</td><td class="xxxx-borders shading">130 (16)</td><td class="xxxr-borders shading">119 (15)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Exchange of sex for money or gifts in past 30 days — no. (%)</td><td class="xxxx-borders">791 (21)</td><td class="xxxx-borders">384 (20)</td><td class="xxxx-borders">407 (22)</td><td class="xxxx-borders">256 (16)</td><td class="xxxx-borders">128 (16)</td><td class="xxxr-borders">128 (16)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Number of sex acts in past 30 days — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">0–4</td><td class="xxxx-borders">1238 (33)</td><td class="xxxx-borders">624 (33)</td><td class="xxxx-borders">614 (32)</td><td class="xxxx-borders">455 (28)</td><td class="xxxx-borders">229 (28)</td><td class="xxxr-borders">226 (28)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">5–10</td><td class="xxxx-borders shading">1373 (36)</td><td class="xxxx-borders shading">702 (37)</td><td class="xxxx-borders shading">671 (35)</td><td class="xxxx-borders shading">609 (38)</td><td class="xxxx-borders shading">310 (38)</td><td class="xxxr-borders shading">299 (37)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">≥11</td><td class="xxxx-borders">1173 (31)</td><td class="xxxx-borders">567 (30)</td><td class="xxxx-borders">606 (32)</td><td class="xxxx-borders">554 (34)</td><td class="xxxx-borders">272 (34)</td><td class="xxxr-borders">282 (35)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Lives with spouse or main partner — no. (%)</td><td class="xxxx-borders shading">530 (14)</td><td class="xxxx-borders shading">239 (13)</td><td class="xxxx-borders shading">291 (15)</td><td class="xxxx-borders shading">278 (17)</td><td class="xxxx-borders shading">144 (18)</td><td class="xxxr-borders shading">134 (17)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Sexually transmitted infection — no./total no. (%)<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Syphilis</td><td class="xxxx-borders shading">44/3389 (1)</td><td class="xxxx-borders shading">21/1702 (1)</td><td class="xxxx-borders shading">23/1687 (1)</td><td class="xxxx-borders shading">26/1252 (2)</td><td class="xxxx-borders shading">10/633 (2)</td><td class="xxxr-borders shading">16/619 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>Neisseria gonorrhoeae</i></td><td class="xxxx-borders">179/3389 (5)</td><td class="xxxx-borders">90/1702 (5)</td><td class="xxxx-borders">89/1687 (5)</td><td class="xxxx-borders">39/1252 (3)</td><td class="xxxx-borders">19/633 (3)</td><td class="xxxr-borders">20/619 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>Chlamydia trachomatis</i></td><td class="xxxx-borders shading">779/3389 (23)</td><td class="xxxx-borders shading">408/1702 (24)</td><td class="xxxx-borders shading">371/1687 (22)</td><td class="xxxx-borders shading">199/1252 (16)</td><td class="xxxx-borders shading">103/633 (16)</td><td class="xxxr-borders shading">96/619 (16)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left"><i>Trichomonas vaginalis</i></td><td class="xbxx-borders">192/3389 (6)</td><td class="xbxx-borders">97/1702 (6)</td><td class="xbxx-borders">95/1687 (6)</td><td class="xbxx-borders">NA</td><td class="xbxx-borders">NA</td><td class="xbxr-borders">NA</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">Percentages may not total 100 because of rounding. NA denotes not applicable.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">The body-mass index is the weight in kilograms divided by the square of the height in meters.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">Testing for sexually transmitted infections was introduced in version 2 of the protocol, so data are not available for 763 trial participants (397 women and 366 men).</div></div></div></figcaption></a><figcaption><div class="caption">Characteristics of the Participants at Baseline, According to Sex.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2031499_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2031499_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2031499/asset/4b8c5f44-9980-40a3-945c-55be1291c3d6/assets/images/large/nejmoa2031499_t2.jpg" height="1451" width="2615" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Cohort and Time Period</th><th class="txxx-borders" colspan="4"><span>Vaccine (N=2695)</span></th><th class="txxx-borders" colspan="4"><span>Placebo (N=2689)</span></th><th class="txxr-borders">Hazard Ratio<br>(95% CI)<a href="#core-t2fn2" role="doc-noteref">†</a></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Participants<br>Evaluated</th><th class="xxxx-borders">Infections<br>Diagnosed</th><th class="xxxx-borders">Person-Yrs</th><th class="xxxx-borders">Infection Rate</th><th class="xxxx-borders">Participants<br>Evaluated</th><th class="xxxx-borders">Infections<br>Diagnosed</th><th class="xxxx-borders">Person-Yrs</th><th class="xxxx-borders">Infection Rate</th><td class="xxxr-borders">&nbsp;</td></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders" colspan="3"><span>number</span></th><th class="xxxx-borders">number/100<br>person-yr</th><th class="xxxx-borders" colspan="3"><span>number</span></th><th class="xxxx-borders">number/100<br>person-yr</th><td class="xxxr-borders">&nbsp;</td></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">mITT cohort (mo 0–24)</td><td class="xxxx-borders shading">2695</td><td class="xxxx-borders shading">138</td><td class="xxxx-borders shading">4098.3</td><td class="xxxx-borders shading">3.4</td><td class="xxxx-borders shading">2689</td><td class="xxxx-borders shading">133</td><td class="xxxx-borders shading">4052.7</td><td class="xxxx-borders shading">3.3</td><td class="xxxr-borders shading">1.02 (0.81–1.30)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">mITT cohort (mo 0–36)</td><td class="xxxx-borders">2695</td><td class="xxxx-borders">151</td><td class="xxxx-borders">4477.9</td><td class="xxxx-borders">3.4</td><td class="xxxx-borders">2689</td><td class="xxxx-borders">143</td><td class="xxxx-borders">4438.7</td><td class="xxxx-borders">3.2</td><td class="xxxr-borders">1.05 (0.83–1.31)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Month 6.5 at-risk cohort (mo 6.5–24)</td><td class="xxxx-borders shading">2430</td><td class="xxxx-borders shading">83</td><td class="xxxx-borders shading">2804.0</td><td class="xxxx-borders shading">3.0</td><td class="xxxx-borders shading">2393</td><td class="xxxx-borders shading">71</td><td class="xxxx-borders shading">2760.6</td><td class="xxxx-borders shading">2.6</td><td class="xxxr-borders shading">1.15 (0.84–1.58)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Sex of participants in the mITT cohort (mo 0–24)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Female</td><td class="xxxx-borders shading">1887</td><td class="xxxx-borders shading">122</td><td class="xxxx-borders shading">2819.9</td><td class="xxxx-borders shading">4.3</td><td class="xxxx-borders shading">1886</td><td class="xxxx-borders shading">117</td><td class="xxxx-borders shading">2787.3</td><td class="xxxx-borders shading">4.2</td><td class="xxxr-borders shading">1.03 (0.80, 1.33)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Male</td><td class="xxxx-borders">808</td><td class="xxxx-borders">16</td><td class="xxxx-borders">1278.4</td><td class="xxxx-borders">1.3</td><td class="xxxx-borders">803</td><td class="xxxx-borders">16</td><td class="xxxx-borders">1265.5</td><td class="xxxx-borders">1.3</td><td class="xxxr-borders">0.99 (0.50, 1.98)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Age of women in the mITT cohort (mo 0–24)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">≤25 yr</td><td class="xxxx-borders">1264</td><td class="xxxx-borders">87</td><td class="xxxx-borders">1832.1</td><td class="xxxx-borders">4.7</td><td class="xxxx-borders">1267</td><td class="xxxx-borders">80</td><td class="xxxx-borders">1829.6</td><td class="xxxx-borders">4.4</td><td class="xxxr-borders">1.08 (0.80, 1.47)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">&gt;25 yr</td><td class="xbxx-borders shading">623</td><td class="xbxx-borders shading">35</td><td class="xbxx-borders shading">987.8</td><td class="xbxx-borders shading">3.5</td><td class="xbxx-borders shading">619</td><td class="xbxx-borders shading">37</td><td class="xbxx-borders shading">957.7</td><td class="xbxx-borders shading">3.9</td><td class="xbxr-borders shading">0.92 (0.58, 1.46)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">Data are shown for the modified intention-to-treat (mITT) cohort during the period from randomization to 24 months (primary analysis), in the mITT cohort from randomization to 36 months (secondary analysis), in the month 6.5 at-risk cohort consisting of the mITT participants who were HIV-1–negative at 6.5 months and at risk for subsequent HIV-1 infection (secondary analysis), and in the mITT cohort according to sex and age among the female participants.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">The listed values are hazard ratios for vaccine as compared with placebo, as estimated by the Cox proportional-hazards model. In addition to hazard ratios, cumulative incidence ratio (CIR) estimates were calculated for vaccine efficacy in the mITT cohort during the period from month 0 to 24 (1.03; 95% CI, 0.81 to 1.31), in the mITT cohort from month 0 to 30 (1.05; 95% CI, 0.81 to 1.36), and in the month 6.5 at-risk cohort (1.12; 95% CI, 0.81 to 1.54). The 30-month analysis corresponds to the 36-month analysis by the Cox proportional-hazards model but was estimated over the time period in which there were at least 150 participants at risk in each trial group.</div></div></div></figcaption></a><figcaption><div class="caption">Rate of HIV-1 Infection and Estimated Hazard Ratios, According to Cohort and Baseline Variables.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2031499_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2031499</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content"><em>UNAIDS data 2018</em>. Geneva: UNAIDS, July 2018 (<a href="https://www.unaids.org/en/resources/documents/2018/unaids-data-2018">https://www.unaids.org/en/resources/documents/2018/unaids-data-2018</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=UNAIDS+data+2018&amp;publication_year=2018" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Simbayi L, Zuma KK, Zungu NP, et al. <em>South African national HIV prevalence, incidence, behaviour and communication survey, 2017: HIV impact assessment summary report</em>. Cape Town, South Africa: Human Sciences Research Council, October 2019.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=South+African+national+HIV+prevalence%2C+incidence%2C+behaviour+and+communication+survey%2C+2017%3A+HIV+impact+assessment+summary+report&amp;publication_year=2019" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. <em>N Engl J Med</em> 2009;361:2209-2220.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_4_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2031499&amp;key=10.1056%2FNEJMoa0908492&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19843557/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000272257100004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Vaccination+with+ALVAC+and+AIDSVAX+to+prevent+HIV-1+infection+in+Thailand.&amp;publication_year=2009&amp;journal=N+Engl+J+Med&amp;pages=2209-2220&amp;doi=10.1056%2FNEJMoa0908492&amp;pmid=19843557" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Gray G, Doherty T, Mohapi L, et al. HIV research in South Africa: advancing life. <em>S Afr Med J</em> 2019;109:36-40.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.7196/SAMJ.2019.v109i11b.14264" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32252866/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=HIV+research+in+South+Africa%3A+advancing+life.&amp;publication_year=2019&amp;journal=S+Afr+Med+J&amp;pages=36-40&amp;doi=10.7196%2FSAMJ.2019.v109i11b.14264&amp;pmid=32252866" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Laher F, Moodie Z, Cohen KW, et al. Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: a randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. <em>PLoS Med</em> 2020;17(2):e1003038-e1003038.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pmed.1003038" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32092060/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000558128100011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+immune+responses+after+a+12-month+booster+in+healthy+HIV-uninfected+adults+in+HVTN+100+in+South+Africa%3A+a+randomized+double-blind+placebo-controlled+trial+of+ALVAC-HIV+%28vCP2438%29+and+bivalent+subtype+C+gp120%2FMF59+vaccines.&amp;publication_year=2020&amp;journal=PLoS+Med&amp;pages=e1003038-e1003038&amp;doi=10.1371%2Fjournal.pmed.1003038&amp;pmid=32092060" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Gilbert PB, Grove D, Gabriel E, et al. A sequential phase 2b trial design for evaluating vaccine efficacy and immune correlates for multiple HIV vaccine regimens. <em>Stat Commun Infect Dis</em> 2011;3:1037-1037.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23181167/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+sequential+phase+2b+trial+design+for+evaluating+vaccine+efficacy+and+immune+correlates+for+multiple+HIV+vaccine+regimens.&amp;publication_year=2011&amp;journal=Stat+Commun+Infect+Dis&amp;pages=1037-1037&amp;pmid=23181167" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Holm S. A simple sequentially rejective multiple test procedure. <em>Scand J Stat</em> 1979;6:65-70.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1979JY78700003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+simple+sequentially+rejective+multiple+test+procedure.&amp;publication_year=1979&amp;journal=Scand+J+Stat&amp;pages=65-70" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">O’Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. <em>Expert Rev Vaccines</em> 2007;6:699-710.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1586/14760584.6.5.699" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17931151/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000250656300015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=MF59+is+a+safe+and+potent+vaccine+adjuvant+that+enhances+protection+against+influenza+virus+infection.&amp;publication_year=2007&amp;journal=Expert+Rev+Vaccines&amp;pages=699-710&amp;doi=10.1586%2F14760584.6.5.699&amp;pmid=17931151" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">O’Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59 — an innately attractive adjuvant formulation. <em>Vaccine</em> 2012;30:4341-4348.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.vaccine.2011.09.061" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22682289/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000306299200009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+mechanism+of+action+of+MF59+%E2%80%94+an+innately+attractive+adjuvant+formulation.&amp;publication_year=2012&amp;journal=Vaccine&amp;pages=4341-4348&amp;doi=10.1016%2Fj.vaccine.2011.09.061&amp;pmid=22682289" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Shen X, Laher F, Moodie Z, et al. HIV-1 vaccine sequences impact V1V2 antibody responses: a comparison of two poxvirus prime gp120 boost vaccine regimens. <em>Sci Rep</em> 2020;10:2093-2093.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41598-020-57491-z" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32034163/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000562828300010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=HIV-1+vaccine+sequences+impact+V1V2+antibody+responses%3A+a+comparison+of+two+poxvirus+prime+gp120+boost+vaccine+regimens.&amp;publication_year=2020&amp;journal=Sci+Rep&amp;pages=2093-2093&amp;doi=10.1038%2Fs41598-020-57491-z&amp;pmid=32034163" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Bekker L-G, Moodie Z, Grunenberg N, et al. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. <em>Lancet HIV</em> 2018;5(7):e366-e378.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r11-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2352-3018(18)30071-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29898870/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000437674000016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Subtype+C+ALVAC-HIV+and+bivalent+subtype+C+gp120%2FMF59+HIV-1+vaccine+in+low-risk%2C+HIV-uninfected%2C+South+African+adults%3A+a+phase+1%2F2+trial.&amp;publication_year=2018&amp;journal=Lancet+HIV&amp;pages=e366-e378&amp;doi=10.1016%2FS2352-3018%2818%2930071-7&amp;pmid=29898870" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r11-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r11-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] the regimen used in the RV144 trial. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r13" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] the RV114 trial and the HVTN 097 trial). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] than with the subtype C vaccine regimen. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Gottardo R, Bailer RT, Korber BT, et al. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. <em>PLoS One</em> 2013;8(9):e75665-e75665.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r12-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pone.0075665" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24086607/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000325220000034" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Plasma+IgG+to+linear+epitopes+in+the+V2+and+V3+regions+of+HIV-1+gp120+correlate+with+a+reduced+risk+of+infection+in+the+RV144+vaccine+efficacy+trial.&amp;publication_year=2013&amp;journal=PLoS+One&amp;pages=e75665-e75665&amp;doi=10.1371%2Fjournal.pone.0075665&amp;pmid=24086607" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r12-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r13" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] the RV114 trial and the HVTN 097 trial). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] correlates of risk in the RV144 trial. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Gray GE, Huang Y, Grunenberg N, et al. Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. <em>Sci Transl Med</em> 2019;11:eaax1880-eaax1880.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/scitranslmed.aax1880" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31534016/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000486430400005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Immune+correlates+of+the+Thai+RV144+HIV+vaccine+regimen+in+South+Africa.&amp;publication_year=2019&amp;journal=Sci+Transl+Med&amp;pages=eaax1880-eaax1880&amp;doi=10.1126%2Fscitranslmed.aax1880&amp;pmid=31534016" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. <em>N Engl J Med</em> 2012;366:1275-1286.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_15_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2031499&amp;key=10.1056%2FNEJMoa1113425&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22475592/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000302343000005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Immune-correlates+analysis+of+an+HIV-1+vaccine+efficacy+trial.&amp;publication_year=2012&amp;journal=N+Engl+J+Med&amp;pages=1275-1286&amp;doi=10.1056%2FNEJMoa1113425&amp;pmid=22475592" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Passmore J-AS, Jaspan HB, Masson L. Genital inflammation, immune activation and risk of sexual HIV acquisition. <em>Curr Opin HIV AIDS</em> 2016;11:156-162.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/COH.0000000000000232" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26628324/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000369652400005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Genital+inflammation%2C+immune+activation+and+risk+of+sexual+HIV+acquisition.&amp;publication_year=2016&amp;journal=Curr+Opin+HIV+AIDS&amp;pages=156-162&amp;doi=10.1097%2FCOH.0000000000000232&amp;pmid=26628324" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Powers KA, Ghani AC, Miller WC, et al. The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. <em>Lancet</em> 2011;378:256-268.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(11)60842-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21684591/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000293201100033" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+role+of+acute+and+early+HIV+infection+in+the+spread+of+HIV+and+implications+for+transmission+prevention+strategies+in+Lilongwe%2C+Malawi%3A+a+modelling+study.&amp;publication_year=2011&amp;journal=Lancet&amp;pages=256-268&amp;doi=10.1016%2FS0140-6736%2811%2960842-8&amp;pmid=21684591" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Robb ML, Rerks-Ngarm S, Nitayaphan S, et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. <em>Lancet Infect Dis</em> 2012;12:531-537.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1473-3099(12)70088-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22652344/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000306045300026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Risk+behaviour+and+time+as+covariates+for+efficacy+of+the+HIV+vaccine+regimen+ALVAC-HIV+%28vCP1521%29+and+AIDSVAX+B%2FE%3A+a+post-hoc+analysis+of+the+Thai+phase+3+efficacy+trial+RV+144.&amp;publication_year=2012&amp;journal=Lancet+Infect+Dis&amp;pages=531-537&amp;doi=10.1016%2FS1473-3099%2812%2970088-9&amp;pmid=22652344" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Vaccari M, Keele BF, Bosinger SE, et al. Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure. <em>J Virol</em> 2013;87:3538-3548.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1128/JVI.02863-12" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23325681/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000315348500050" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Protection+afforded+by+an+HIV+vaccine+candidate+in+macaques+depends+on+the+dose+of+SIVmac251+at+challenge+exposure.&amp;publication_year=2013&amp;journal=J+Virol&amp;pages=3538-3548&amp;doi=10.1128%2FJVI.02863-12&amp;pmid=23325681" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Rolland M, Edlefsen PT, Larsen BB, et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. <em>Nature</em> 2012;490:417-420.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature11519" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22960785/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000309918500049" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Increased+HIV-1+vaccine+efficacy+against+viruses+with+genetic+signatures+in+Env+V2.&amp;publication_year=2012&amp;journal=Nature&amp;pages=417-420&amp;doi=10.1038%2Fnature11519&amp;pmid=22960785" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Rademeyer C, Korber B, Seaman MS, et al. Features of recently transmitted HIV-1 clade C viruses that impact antibody recognition: implications for active and passive immunization. <em>PLoS Pathog</em> 2016;12(7):e1005742-e1005742.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.ppat.1005742" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27434311/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000383366400027" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Features+of+recently+transmitted+HIV-1+clade+C+viruses+that+impact+antibody+recognition%3A+implications+for+active+and+passive+immunization.&amp;publication_year=2016&amp;journal=PLoS+Pathog&amp;pages=e1005742-e1005742&amp;doi=10.1371%2Fjournal.ppat.1005742&amp;pmid=27434311" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Los Alamos National Laboratory. <em>HIV databases</em> (<a href="http://www.hiv.lanl.gov/">http://www.hiv.lanl.gov/</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=HIV+databases" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Li SS, Gilbert PB, Tomaras GD, et al. FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. <em>J Clin Invest</em> 2014;124:3879-3890.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1172/JCI75539" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25105367/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000341168100023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=FCGR2C+polymorphisms+associate+with+HIV-1+vaccine+protection+in+RV144+trial.&amp;publication_year=2014&amp;journal=J+Clin+Invest&amp;pages=3879-3890&amp;doi=10.1172%2FJCI75539&amp;pmid=25105367" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Gartland AJ, Li S, McNevin J, et al. Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial. <em>J Virol</em> 2014;88:8242-8255.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1128/JVI.01164-14" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24829343/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000338924400005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Analysis+of+HLA+A%2A02+association+with+vaccine+efficacy+in+the+RV144+HIV-1+vaccine+trial.&amp;publication_year=2014&amp;journal=J+Virol&amp;pages=8242-8255&amp;doi=10.1128%2FJVI.01164-14&amp;pmid=24829343" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Prentice HA, Tomaras GD, Geraghty DE, et al. HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition. <em>Sci Transl Med</em> 2015;7:296ra112-296ra112.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/scitranslmed.aab4005" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26180102/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000358738400005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=HLA+class+II+genes+modulate+vaccine-induced+antibody+responses+to+affect+HIV-1+acquisition.&amp;publication_year=2015&amp;journal=Sci+Transl+Med&amp;pages=296ra112-296ra112&amp;doi=10.1126%2Fscitranslmed.aab4005&amp;pmid=26180102" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Lassaunière R, Tiemessen CT. Variability at the FCGR locus: characterization in Black South Africans and evidence for ethnic variation in and out of Africa. <em>Genes Immun</em> 2016;17:93-104.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/gene.2015.60" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26673965/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000371902100003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Variability+at+the+FCGR+locus%3A+characterization+in+Black+South+Africans+and+evidence+for+ethnic+variation+in+and+out+of+Africa.&amp;publication_year=2016&amp;journal=Genes+Immun&amp;pages=93-104&amp;doi=10.1038%2Fgene.2015.60&amp;pmid=26673965" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">Hertz T, Logan MG, Rolland M, et al. A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trial. <em>Vaccine</em> 2016;34:5792-5801.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.vaccine.2016.09.054" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27756485/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000387196800014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+study+of+vaccine-induced+immune+pressure+on+breakthrough+infections+in+the+Phambili+phase+2b+HIV-1+vaccine+efficacy+trial.&amp;publication_year=2016&amp;journal=Vaccine&amp;pages=5792-5801&amp;doi=10.1016%2Fj.vaccine.2016.09.054&amp;pmid=27756485" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="core-r27" class="citations"><div class="citation"><div class="citation-content">Tshabalala M, Mellet J, Pepper MS. Human leukocyte antigen diversity: a southern African perspective. <em>J Immunol Res</em> 2015;2015:746151-746151.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1155/2015/746151" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26347896/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000360164900001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Human+leukocyte+antigen+diversity%3A+a+southern+African+perspective.&amp;publication_year=2015&amp;journal=J+Immunol+Res&amp;pages=746151-746151&amp;doi=10.1155%2F2015%2F746151&amp;pmid=26347896" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/editorial" class="issue-item_type">Editorial</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Mar 24, 2021</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMe2102358" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Uhambo — Twists and Turns on the Journey to an Efficacious HIV-1 Vaccine</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">M.B. Feinberg</span></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 10, 2025</div><div class="nejm-widget_item"><div><span> Binghamton, New York</span></div><div><span>Internal Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/879071/internal-medicine-guthrie-lourdes-binghamton-ny/?query=fjwp&amp;rid=899">Internal Medicine - Guthrie Lourdes - Binghamton, NY</a></div></div><div class="nejm-widget_item"><div><span> Port Jefferson, New York</span></div><div><span>Neurology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/848973/general-neurologist-mather-hospital/?query=fjwp&amp;rid=3059">General Neurologist, Mather Hospital</a></div></div><div class="nejm-widget_item"><div><span> Suffern, New York</span></div><div><span>Otolaryngology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/877992/pediatric-otolaryngologist/?query=fjwf&amp;rid=22466">Pediatric Otolaryngologist</a></div></div><div class="nejm-widget_item"><div><span> Cleveland, Ohio</span></div><div><span>Chiefs / Directors / Dept. Heads</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/878331/neurosurgery-vice-chair-department-of-neurosurgery-regional-practices/?query=fjwf&amp;rid=2201">Neurosurgery: Vice-Chair, Department of Neurosurgery - Regional Practices</a></div></div><div class="nejm-widget_item"><div><span> Texas</span></div><div><span>Gastroenterology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/887236/gastroenterology-near-houston-tx-4-5-day-week-ercp-900k-1m-annually/?query=fjwf&amp;rid=5263">Gastroenterology | Near Houston, TX | 4.5 Day Week | ERCP | $900K-1M Annually</a></div></div><div class="nejm-widget_item"><div><span> Stony Brook, New York</span></div><div><span>Infectious Disease</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/893427/associate-full-professor-of-empire-innovation-internal-medicine-infectious-diseases-tenure-track-/?query=fjws&amp;rid=121">Associate/Full Professor of Empire Innovation, Internal Medicine, Infectious Diseases (Tenure-Track)</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128720&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejmai%2Fregister%2Faifallpdf24%3Fpromo%3DOAFQF4NA%26query%3Dcm-rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Daifallpdf24&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2031499&amp;pubId=41289679&amp;placeholderId=101337&amp;productId=1007" target="_blank"><img src="/sda/128720/NEJ-AI-Fall24-300x250---002.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d673c4956d77c0-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d673c4956d77c0-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d673c4956d77c0-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$648277510$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$648277510$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$648277510$--></div></div><div class="mlt-body"><!--?lit$648277510$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/perspective" target="_self"><!--?lit$648277510$-->Perspective</a> <span class="mlt-article-site-label"><!--?lit$648277510$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$648277510$-->Apr 24, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMp2415893?query=recirc_Semantic" target="_self">An HIV Vaccine in the Era of Twice-Yearly Lenacapavir for PrEP — Essential or Irrelevant?</a></div><div class="mlt-article-authors"><!--?lit$648277510$-->L.P. Jatt and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$648277510$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$648277510$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$648277510$-->Mar 18, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2031738?query=recirc_Semantic" target="_self">Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition</a></div><div class="mlt-article-authors"><!--?lit$648277510$-->L. Corey and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$648277510$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$648277510$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$648277510$-->Apr 20, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2216480?query=recirc_Semantic" target="_self">Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants</a></div><div class="mlt-article-authors"><!--?lit$648277510$-->B. Kampmann and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/editorial" target="_self"><!--?lit$648277510$-->Editorial</a> <span class="mlt-article-site-label"><!--?lit$648277510$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$648277510$-->Mar 18, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMe2101131?query=recirc_Semantic" target="_self">The AMP Trials — A Glass Half Full</a></div><div class="mlt-article-authors"><!--?lit$648277510$-->B.D. Walker</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$648277510$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$648277510$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$648277510$-->Feb 20, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2407293?query=recirc_Semantic" target="_self">Low-Dose Yellow Fever Vaccine in Adults in Africa</a></div><div class="mlt-article-authors"><!--?lit$648277510$-->D. Kimathi and Others</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2031499?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2031499" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2031499.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2031499"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMp2101874" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Medicare’s New Device-Coverage Pathway — Breakthrough or Breakdown?</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa2019380" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f0" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2031499_f0.jpg"><img src="/cms/10.1056/NEJMoa2031499/asset/2cd64952-8529-4ebb-b4c1-7cb0e8086e5f/assets/images/large/nejmoa2031499_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title"></div><div class="fv__item__description"><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2031499_f1.jpg"><img src="/cms/10.1056/NEJMoa2031499/asset/b81de1e2-3439-4d27-adc5-3d454a01dde3/assets/images/large/nejmoa2031499_f1.jpg" height="2663" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Kaplan–Meier Analysis of HIV-1 Infection in Three Cohorts.</div><div class="notes"><div role="doc-footnote">Shown are data for the cumulative incidence of human immunodeficiency virus type 1 (HIV-1) infection among the participants in the modified intention-to-treat cohort who were evaluated during the period from randomization to 24 months (primary analysis cohort) (Panel A), in the cohort of participants who were HIV-1–negative at month 6.5 and were at risk for subsequent HIV-1 infection (month 6.5 at-risk cohort) (Panel B), and in the modified intention-to-treat cohort during the period from randomization to month 36 (Panel C). The apparent uptick in the vaccine curve at month 36 is due to a single infection among the remaining 11 participants at risk. In each panel, the inset shows the same data on an expanded y axis; in Panel C, the vaccine curve at 36 months has been cut off at 10% for graphical presentation.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2031499_f2.jpg"><img src="/cms/10.1056/NEJMoa2031499/asset/73300005-7fba-465d-90cd-3ea4655629a2/assets/images/large/nejmoa2031499_f2.jpg" height="3076" width="2640" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Kaplan–Meier Analysis of HIV-1 Infection, According to Sex and Women’s Age.</div><div class="notes"><div role="doc-footnote">Shown is the cumulative incidence of HIV-1 infection in the modified intention-to-treat cohort during the period from randomization to 24 months, according to two prespecified baseline variables: sex (Panel A) and women’s age (Panel B). In each panel, the inset shows the same data on an expanded y axis.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Characteristics of the Participants at Baseline, According to Sex.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Rate of HIV-1 Infection and Estimated Hazard Ratios, According to Cohort and Baseline Variables.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/384/12" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 384 No. 12</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Mar 25, 2021</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2035807" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">T. Powles and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Mar 25, 2021</span></li><li data-toggle="tooltip" data-original-title="Visual Abstract" class="issue-item_meta-item"><span role="img" aria-label="Visual Abstract" tabindex="0" class="issue-item_visualAbstract"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-visual"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2019380" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">T. Bieber and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Mar 25, 2021</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2028395" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">P.N. Newsome and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2031499%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2031499&amp;pubId=41289679&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2031499%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2031499&amp;pubId=41289679&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id04890112241947193" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d673c4956d77c0-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d673c4956d77c0-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d673c4956d77c0-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d673c4956d77c0-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d673c4956d77c0-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d673c4956d77c0-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d673c4956d77c0-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d673c4956d77c0-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d673c4956d77c0-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d673c4956d77c0-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d673c488b277c0',t:'MTc0OTUzMzE2OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d673c488b277c0&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_h9ofvi0awljanqxe2o86rs00vo78a91hsnvy12an" data-transactionid="h9ofvi0awljanqxe2o86rs00vo78a91hsnvy12an" id="captureIFrame_h9ofvi0awljanqxe2o86rs00vo78a91hsnvy12an" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="h9ofvi0awljanqxe2o86rs00vo78a91hsnvy12an" target="captureIFrame_h9ofvi0awljanqxe2o86rs00vo78a91hsnvy12an" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_h9ofvi0awljanqxe2o86rs00vo78a91hsnvy12an" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_h9ofvi0awljanqxe2o86rs00vo78a91hsnvy12an" name="capture_screen"><input id="capture_signIn_js_version_h9ofvi0awljanqxe2o86rs00vo78a91hsnvy12an" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_h9ofvi0awljanqxe2o86rs00vo78a91hsnvy12an" name="js_version"><input id="capture_signIn_transactionId_h9ofvi0awljanqxe2o86rs00vo78a91hsnvy12an" data-capturefield="undefined" value="h9ofvi0awljanqxe2o86rs00vo78a91hsnvy12an" type="hidden" class="capture_transactionId_h9ofvi0awljanqxe2o86rs00vo78a91hsnvy12an" name="capture_transactionId"><input id="capture_signIn_form_h9ofvi0awljanqxe2o86rs00vo78a91hsnvy12an" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_h9ofvi0awljanqxe2o86rs00vo78a91hsnvy12an" name="form"><input id="capture_signIn_flow_h9ofvi0awljanqxe2o86rs00vo78a91hsnvy12an" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_h9ofvi0awljanqxe2o86rs00vo78a91hsnvy12an" name="flow"><input id="capture_signIn_client_id_h9ofvi0awljanqxe2o86rs00vo78a91hsnvy12an" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_h9ofvi0awljanqxe2o86rs00vo78a91hsnvy12an" name="client_id"><input id="capture_signIn_redirect_uri_h9ofvi0awljanqxe2o86rs00vo78a91hsnvy12an" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_h9ofvi0awljanqxe2o86rs00vo78a91hsnvy12an" name="redirect_uri"><input id="capture_signIn_response_type_h9ofvi0awljanqxe2o86rs00vo78a91hsnvy12an" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_h9ofvi0awljanqxe2o86rs00vo78a91hsnvy12an" name="response_type"><input id="capture_signIn_flow_version_h9ofvi0awljanqxe2o86rs00vo78a91hsnvy12an" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_h9ofvi0awljanqxe2o86rs00vo78a91hsnvy12an" name="flow_version"><input id="capture_signIn_settings_version_h9ofvi0awljanqxe2o86rs00vo78a91hsnvy12an" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_h9ofvi0awljanqxe2o86rs00vo78a91hsnvy12an" name="settings_version"><input id="capture_signIn_locale_h9ofvi0awljanqxe2o86rs00vo78a91hsnvy12an" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_h9ofvi0awljanqxe2o86rs00vo78a91hsnvy12an" name="locale"><input id="capture_signIn_recaptcha_version_h9ofvi0awljanqxe2o86rs00vo78a91hsnvy12an" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_h9ofvi0awljanqxe2o86rs00vo78a91hsnvy12an" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div><vul-keftqyjbwadf></vul-keftqyjbwadf><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2031499?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=2-10"></script><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div></body></html>